

Supporting information

***N*-arylsulfonamide-based adenosine analogues to target RNA cap *N*7-methyltransferase nsp14 of SARS-CoV-2**

Rostom Ahmed-Belkacem,^a Joris Troussier,^a Adrien Delpal,^b Bruno Canard,^b Jean-Jacques Vasseur,^a Etienne Decroly^{*b} and Françoise Debart^{*a}

Table of contents

Detailed synthetic procedures and spectral characterization data for compounds 1-53.....	2
General information.....	2
Synthesis of <i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylthioether linker (33-40 ; 1-8)	2
Synthesis of <i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylsulfone linker (41-45 ; 9-13)	7
Synthesis of <i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylamino linker (46-53 ; 14-18)	11
<i>N</i> -propargyl- <i>N</i> -ethylsulfonamide reagents (J-M).....	15
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -methyltriazole linker (19-31).....	16
HPLC analysis of final compounds 1-31.....	21
¹H-NMR and ¹³C-NMR spectra of compounds 1-53.....	32
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylthioether linker (33-40 and 1-8).....	32
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylsulfone linker (41-45 and 9-13).....	48
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylamino linker (46-53 and 14-18).....	58
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -methyltriazole linker (19-31).....	71
<i>N</i> -ethyl- <i>N</i> -propargyl reagents (J-M).....	84
IC₅₀ curves of compounds 1-13 against SARS-CoV-2 <i>N</i>7-MTase monitored by FBA.....	88
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylthioether linker (1-8).....	88
<i>N</i> -arylsulfonamide adenosine analogues with an <i>N</i> -ethylsulfone linker (9-13).....	89

Detailed synthetic procedures and spectral characterization data for compounds 1-53


General information

All dry solvents and reagents were purchased from commercial suppliers and were used without further purification. Thin-layer chromatography (TLC) analyses were carried out on silica plate 60 F₂₅₄. Purifications by column chromatography were performed using Biotage Isolera 1 system or Buchi C-815 system with Flash-Pure cartridges (Buchi). NMR experiments were recorded on Bruker 500 or 600 MHz spectrometers at 20°C. HRMS analyses were obtained with electrospray ionization (ESI) in positive mode on a Q-TOF Micromass spectrometer. Analytical HPLC was performed on a UHPLC ThermoScientific Ultimate 3000 system equipped with a LPG-3400RS pump, a DAD 3000 detector and an WPS-3000TBRS Autosampler, Column Oven TCC-3000SD. Final compounds **1-31** were stored at -20 °C for several months without any degradation.

Synthesis of *N*-arylsulfonamide adenosine analogues with an *N*-ethylthioether linker (**33-40** ; **1-8**)


N-(2-((((3*aS*,4*S*,6*R*,6*aR*)-6-(6-amino-9*H*-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl)thio)ethyl)benzenesulfonamide (**33**). Following method **A** with **32** (100 mg, 0.27 mmol, 1.00 eq) and benzenesulfonyl chloride (60 mg, 0.34 mmol, 1.25 eq), **33** was obtained as a white solid (77 mg, 56%). *R*_f 0.56 (1:9 MeOH/DCM).

¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.31 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 7.79 – 7.76 (m, 2H, H_{Ar}) ; 7.65 – 7.60 (m, 1H, H_{Ar}) ; 7.58 (m, 2H, H_{Ar}) ; 7.34 (br s, 2H, NH₂) ; 6.15 (d, *J* = 2.5 Hz, 1H, H_{1'}) ; 5.47 (dd, *J* = 6.2, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, *J* = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.17 (m, 1H, H_{4'}) ; 2.87 (t, *J* = 7.2 Hz, 2H, CH₂ Et) ; 2.76 (dd, *J* = 13.5, 8.0 Hz, 1H, H_{5'}) ; 2.69 (dd, *J* = 13.5, 6.4 Hz, 1H, H_{5''}) ; 2.54 – 2.47 (m, 2H, CH₂ Et) ; 1.52 (s, 3H, CH₃ isopr) ; 1.32 (s, 3H, CH₃ isopr). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 140.5 (C_{q Ar}) ; 140.0 (C₈) ; 132.4 (C_{Ar}) ; 129.2 (C_{Ar}) ; 126.9 (C_{Ar}) ; 119.1 (C₅) ; 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.5 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 42.6 (CH₂ Et) ; 33.3 (C_{5'}) ; 31.0 (CH₂ Et) ; 26.9 (CH₃ isopr) ; 25.1 (CH₃ isopr). HRMS (ESI+): *m/z* calc. for C₂₁H₂₇N₆O₅S₂ [M+H]⁺: 507.1479, Found 507.1483.




N-(2-((((3*aS*,4*S*,6*R*,6*aR*)-6-(6-amino-9*H*-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-nitrobenzenesulfonamide (**34**). Following method **A** with **32** (150 mg, 0.41 mmol, 1.00 eq) and 4-nitrobenzenesulfonyl chloride (113 mg, 0.51 mmol, 1.25 eq), **34** was obtained as a white solid (180 mg, 80%). *R*_f 0.48 (1:9 MeOH/DCM).

¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.44 – 8.37 (m, 2H, 2H_{Ar}) ; 8.30 (s, 1H, H₈) ; 8.19 – 8.11 (m, 2H, H₂, NH) ; 8.06 – 7.99 (m, 2H, 2H_{Ar}) ; 7.33 (br. s, 2H, NH₂) ; 6.14 (d, *J* = 2.4 Hz, 1H, H_{1'}) ; 5.47 (dd, *J* = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.95 (dd, *J* = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.16 (td, *J* = 6.5, 3.0 Hz, 1H, H_{4'}) ; 2.93 (t, *J* = 7.1 Hz, 2H, CH₂ Et) ; 2.76 (dd, *J* = 13.6, 7.8 Hz, 1H, H_{5'}) ; 2.71 (dd, *J* = 13.5, 6.5 Hz, 1H, H_{5''}) ; 2.52 (m, 2H, CH₂ Et) ; 1.52 (s, 3H, CH₃ isopr) ; 1.32 (s, 3H, CH₃ isopr). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.7 (C₂) ; 149.5 (C_{q Ar}) ; 148.7 (C₄) ; 146.1 (C_{q Ar}) ; 140.0 (C₈) ; 128.0 (CH_{Ar}) ; 124.6 (CH_{Ar}) ; 119.1 (C₅), 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.6 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 42.5 (CH₂ Et) ; 33.2 (C_{5'}) ; 31.1 (CH₂ Et) ; 26.9 (CH₃ isopr) ; 25.1 (CH₃ isopr). HRMS (ESI+): *m/z* calc. for C₂₁H₂₆N₇O₇S₂ [M+H]⁺: 552.1330, Found 552.1340.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-

cyanobenzenesulfonamide (35). Following method A with **32** (150 mg, 0.41 mmol, 1.00 eq) and 4-cyanobenzenesulfonyl chloride (103 mg, 0.51 mmol, 1.25 eq), **35** was obtained as a white solid (129 mg, 59%). R_f 0.38 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 8.09 – 8.05 (m, 2H, H_{Ar}) ; 7.94 – 7.91 (m, 2H, H_{Ar}) ; 7.34 (br s, 2H, NH₂) ; 6.15 (d, J = 2.4, 1H, H_{1'}) ; 5.47 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, J = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.17 (td, J = 6.8, 2.7 Hz, 1H, H_{4'}) ; 2.90 (t, J = 7.2 Hz, 2H, CH_{2 Et}) ; 2.76 (dd, J = 13.6, 7.8 Hz, 1H, H_{5'}) ; 2.71 (dd, J = 13.6, 6.5 Hz, 1H, H_{5''}) ; 2.53 – 2.47 (m, 2H, CH_{2 Et}) ; 1.52 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 144.7 (CN) ; 140.0 (C₄) ; 133.4 (C_{Ar}) ; 127.2 (C_{Ar}) ; 119.1 (C₅) ; 117.7 (C_{q Ar}) ; 114.9 (C_{q Az}) ; 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.6 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 42.5 (CH_{2 Et}) ; 33.2 (C_{5'}) ; 31.1 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.13 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₆N₇O₅S₂ [M+H]⁺: 532.1437, Found 532.1443.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-

methylbenzenesulfonamide (36). Following method A with **32** (150 mg, 0.41 mmol, 1.00 eq) and 4-methylbenzenesulfonyl chloride (98 mg, 0.51 mmol, 1.25 eq), **36** was obtained as a white solid (164 mg, 77%). R_f 0.46 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 7.65 (d, J = 8.2 Hz, 2H, H_{Ar}) ; 7.37 (d, J = 8.3 Hz, 2H, H_{Ar}) ; 7.34 (br s, 2H, NH₂) ; 6.15 (d, J = 2.3 Hz, 1H, H_{1'}) ; 5.46 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, J = 6.3, 2.8 Hz, 1H, H_{3'}) ; 4.19 – 4.14 (m, 1H, H_{4'}) ; 2.84 (t, J = 7.2 Hz, 2H, CH_{2 Et}) ; 2.77 (dd, J = 13.6, 8.1 Hz, 1H, H_{5'}) ; 2.71 (dd, J = 13.5, 6.4 Hz, 1H, H_{5''}) ; 2.51 – 2.47 (m, 2H, CH_{2 Et}) ; 2.37 (s, 3H, CH_{3 Ar}) ; 1.52 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.2 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 142.6 (C_{q Ar}) ; 140.0 (C₈) ; 137.6 (C_{q Ar}) ; 129.6 (C_{Ar}) ; 126.5 (C_{Ar}) ; 119.1 (C₅) ; 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.5 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 42.7 (CH_{2 Et}) ; 33.3 (C_{5'}) ; 31.0 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.1 (CH_{3 isopr}) ; 20.9 (CH_{3 Ar}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₉N₆O₅S₂ [M+H]⁺: 521.1635, Found 521.1638.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-

(trifluoromethyl)benzenesulfonamide (37). Following method A with **32** (150 mg, 0.41 mmol, 1.00 eq) and 4-trifluoromethylbenzenesulfonyl chloride (125 mg, 0.51 mmol, 1.25 eq), **37** was obtained as a white solid (157 mg, 67%). R_f 0.51 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 8.04 (br s, 1H, NH) ; 8.00 – 7.95 (m, 4H, H_{Ar}) ; 7.34 (s, 2H, NH₂) ; 6.15 (d, J = 2.4 Hz, 1H, H_{1'}) ; 5.47 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, J = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.17 (m, 1H, H_{4'}) ; 2.91 (t, J = 7.1 Hz, 2H, CH_{2 Et}) ; 2.78-2.75 (dd, J = 13.6, 7.9 Hz, 1H, H_{5'}) ; 2.73-2.69 (dd, J = 13.6, 6.5 Hz, 1H, H_{5''}) ; 2.54 – 2.51 (m, 2H, CH_{2 Et}) ; 1.51 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 144.5 (C_{q Ar}) ; 140.0 (C₈) ; 132.4, 132.2, 132.0, 131.8 (C_{q Ar}) ; 127.4 (C_{Ar}) ; 126.5 (C_{Ar}) ; 126.2, 124.4, 122.6, 120.8 (CF₃) ; 119.1 (C₅) ; 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.6 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 42.6 (CH_{2 Et}) ; 33.3 ; 31.1 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.1 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₆F₃N₆O₅S₂ [M+H]⁺: 575.1358, Found 575.1364.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-2-nitrobenzenesulfonamide (38).

Following method A with **32** (110 mg, 0.30 mmol, 1.00 eq) and 2-nitrobenzenesulfonyl chloride (83 mg, 0.38 mmol, 1.25 eq), **38** was obtained as a white solid (117 mg, 71%). R_f 0.41 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.16 (br s, 1H, NH) ; 8.15 (s, 1H, H₂) ; 7.99 – 7.94 (m, 2H, H_{Ar}) ; 7.86 – 7.83 (m, 2H, H_{Ar}) ; 7.35 (s, 2H, NH₂) ; 6.15 (d, J = 2.4 Hz, 1H, H_{1'}) ; 5.47 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, J = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.18 (m, 1H, H_{4'}) ; 3.04 (t, J = 7.1 Hz, 2H, CH_{2 Et}) ; 2.78-2.74 (dd, J = 13.6, 7.9 Hz, 1H, H_{5'}) ; 2.73-2.69 (dd, J = 13.5, 6.4 Hz, 1H, H_{5''}) ; 2.59 – 2.53 (m, 2H, CH_{2 Et}) ; 1.52 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 147.5 (C_{q Ar}) ; 140.0 (C₈) ; 134.1 (C_{Ar}) ; 132.8 (C_{q Ar}) ; 132.7 (C_{Ar}) ; 129.4 (C_{Ar}) ; 124.5 (C_{Ar}) ; 119.2 (C₅) ; 113.3 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.5 (C_{4'}) ; 83.3 (C_{3'}) ; 83.2 (C_{2'}) ; 42.7 (CH_{2 Et}) ; 33.2 (C_{5'}) ; 31.1 (CH_{2 Et}) ; 27.0 (CH_{3 isopr}) ; 25.2 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₁H₂₆N₇O₇S₂ [M+H]⁺: 552.1330, Found 552.1330.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-methoxy-2-nitrobenzenesulfonamide (39).

Following method A with **32** (110 mg, 0.30 mmol, 1.00 eq) and 2-nitro-4-methoxybenzenesulfonyl chloride (94 mg, 0.38 mmol, 1.25 eq), **39** was obtained as a white solid (98 mg, 56%). R_f 0.5 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.15 (s, 1H, H₂) ; 7.96 (br s, 1H, NH) ; 7.87 (m, 1H, H_{Ar}) ; 7.56 (m, 1H, H_{Ar}) ; 7.34 (m, 3H, NH₂, H_{Ar}) ; 6.15 (d, J = 2.4 Hz, 1H, H_{1'}) ; 5.47 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.97 (dd, J = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.19 (m, 1H, H_{4'}) ; 3.90 (s, 3H, OCH₃) ; 3.00 (t, J = 7.1 Hz, 2H, CH_{2 Et}) ; 2.79-2.75 (dd, J = 13.4, 8.0 Hz, 1H, H_{5'}) ; 2.74-2.70 (dd, J = 13.5, 6.4 Hz, 1H, H_{5''}) ; 2.57 – 2.53 (m, 2H, CH_{2 Et}) ; 1.52 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 162.5 (C_{q Ar}) ; 156.2 (C₆) ; 152.8 (C₂) ; 149.1 (C_{q Ar}) ; 148.8 (C₄) ; 140.0 (C₈) ; 131.4 (C_{Ar}) ; 124.2 (C_{q Ar}) ; 119.2 (C₅) ; 117.4 (C_{Ar}) ; 113.3 (C_{q isopr}) ; 109.9 (C_{Ar}) ; 89.2 (C_{1'}) ; 85.5 (C_{4'}) ; 83.3 (C_{3'}) ; 83.1 (C_{2'}) ; 56.7 (OCH₃) ; 42.6 (CH_{2 Et}) ; 33.3 (C_{5'}) ; 31.0 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.1 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₈N₇O₈S₂ [M+H]⁺: 582,1435, Found 582,1433.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)thio)ethyl)-4-chloro-2-nitrobenzenesulfonamide (40).

Following method A with **32** (120 mg, 0.33 mmol, 1.00 eq) and 2-nitro-4-chlorobenzenesulfonyl chloride (105 mg, 0.41 mmol, 1.25 eq), **40** was obtained as a white solid (85 mg, 44%). R_f 0.56 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.24 (m, 1H, H_{Ar}) ; 8.15 (s, 1H, H₂) ; 7.97 (m, 1H, H_{Ar}) ; 7.94 (m, 1H, H_{Ar}) ; 7.34 (br s, 2H, NH₂) ; 6.15 (d, J = 2.4 Hz, 1H, H_{1'}) ; 5.47 (dd, J = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.96 (dd, J = 6.3, 2.9 Hz, 1H, H_{3'}) ; 4.18 (m, 1H, H_{4'}) ; 3.04 (t, J = 7.1 Hz, 2H, CH_{2 Et}) ; 2.79-2.75 (dd, J = 13.4, 7.9 Hz, 1H, H_{5'}) ; 2.74-2.70 (dd, J = 13.6, 6.4 Hz, 1H, H_{5''}) ; 2.57 – 2.54 (m, 2H, CH_{2 Et}) ; 1.52 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.2 (C₆) ; 152.8 (C₂) ; 148.7 (C₄) ; 148.0 (C_{q Ar}) ; 140.0 (C₈) ; 138.1 (C_{q Ar}) ; 132.6 (C_{Ar}) ; 131.7 (C_{q Ar}) ; 131.1 (C_{Ar}) ; 124.4 (C_{Ar}) ; 119.2 (C₅) ; 113.4 (C_{q isopr}) ; 89.2 (C_{1'}) ; 85.5 (C_{4'}) ; 83.3 (C_{3'}) ; 83.2 (C_{2'}) ; 42.7 (CH_{2 Et}) ; 33.2 (C_{5'}) ; 31.1 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.2 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₁H₂₅ClN₇O₇S₂ [M+H]⁺: 586.0940, Found 586.0950.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)benzenesulfonamide (1).

Following method C with intermediate 33 (70 mg, 0.14 mmol, 1.00 eq), 1 was obtained as a white solid (53 mg, 82%). R_f 0.14 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 7.79 – 7.74 (m, 2H, H_{Ar}) ; 7.64 – 7.60 (m, 1H, H_{Ar}) ; 7.59 – 7.55 (m, 2H, H_{Ar}) ; 7.27 (s, 2H, NH₂) ; 5.87 (d, J = 5.7 Hz, 1H, H_{1'}) ; 5.51 (br s, 1H, OH_{2'}) ; 5.32 (br s, 1H, OH_{3'}) ; 4.71 (t, J = 5.4 Hz, 1H, H_{2'}) ; 4.11 (m, 1H, H_{3'}) ; 3.97 – 3.92 (m, 1H, H_{4'}) ; 2.93 – 2.83 (m, 3H, H_{5'}, CH₂ Et) ; 2.79 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}) ; 2.53 (m, 2H, CH₂ Et). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.4 (C₄) ; 140.5 (C_q Ar) ; 139.8 (C₈) ; 132.4 (C_{Ar}) ; 129.2 (C_{Ar}) ; 126.4 (C_{Ar}) ; 119.2 (C₅) ; 87.4 (C_{1'}) ; 83.7 (C_{4'}) ; 72.6 (C_{2'}) ; 72.5 (C_{3'}) ; 42.7 (CH₂ Et) ; 33.9 (C_{5'}) ; 31.5 (CH₂ Et). **HRMS** (ESI+): m/z calc. for C₁₈H₂₃N₆O₅S₂ [M+H]⁺: 467.1171, Found 467.1176.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-nitrobenzenesulfonamide (2).

Following method C with intermediate 34 (170 mg, 0.31 mmol, 1.00 eq), 2 was obtained as a white solid (103 mg, 65%). R_f 0.14 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.43 – 8.37 (m, 2H, H_{Ar}) ; 8.31 (s, 1H, H₈) ; 8.15 (br s, 1H, NH) ; 8.14 (s, 1H, H₂) ; 8.05 – 8.01 (m, 2H, H_{Ar}) ; 7.26 (br s, 2H, NH₂) ; 5.86 (d, J = 5.6 Hz, 1H, H_{1'}) ; 5.48 (d, J = 6.0 Hz, 1H, OH_{2'}) ; 5.28 (br s, 1H, OH_{3'}) ; 4.71 (dd, J = 11.0, 5.6 Hz, 1H, H_{2'}) ; 4.11 (t, J = 4.2 Hz, 1H, H_{3'}) ; 3.94 (m, 1H, H_{4'}) ; 2.98 (m, 2H, CH₂ Et) ; 2.87 (dd, J = 13.8, 5.7 Hz, 1H, H_{5'}) ; 2.80 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}) ; 2.80 (dd, J = 13.8, 7.1 Hz, 1H) ; 2.61 – 2.52 (m, 2H, CH₂ Et). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.6 (C_q Ar) ; 149.4 (C₄) ; 146.1 (C_q Ar) ; 139.8 (C₈) ; 128.0 (C_{Ar}) ; 124.6 (C_{Ar}) ; 119.2 (C₅) ; 87.4 (C_{1'}) ; 83.8 (C_{4'}) ; 72.6 (C_{2'}) ; 72.5 (C_{3'}) ; 42.7 (CH₂ Et) ; 33.8 (C_{5'}) ; 31.6 (CH₂ Et). **HRMS** (ESI+): m/z calc. for C₁₈H₂₂N₇O₇S₂ [M+H]⁺: 512.1017, Found 512.1011.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-cyanobenzenesulfonamide (3).


Following method C with intermediate 35 (124 mg, 0.23 mmol, 1.00 eq), 3 was obtained as a white solid (100 mg, 87%). R_f 0.11 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 8.09 (s, 1H, NH) ; 8.07 – 8.05 (m, 2H, H_{Ar}) ; 7.94 – 7.91 (m, 2H, H_{Ar}) ; 7.27 (s, 2H, NH₂) ; 5.87 (d, J = 5.6 Hz, 1H, H_{1'}) ; 5.49 (d, J = 5.8 Hz, 1H, OH_{2'}) ; 5.29 (d, J = 3.9 Hz, 1H, OH_{3'}) ; 4.71 (q, J = 5.3 Hz, 1H, H_{2'}) ; 4.11 (m, 1H, H_{3'}) ; 3.95 (ddd, J = 6.9, 5.7, 3.9 Hz, 1H, H_{4'}) ; 2.95 (m, 2H, CH₂ Et) ; 2.87 (dd, J = 13.8, 5.7 Hz, 1H, H_{5'}) ; 2.80 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}) ; 2.55 (m, 2H, CH₂ Et). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.4 (C₄) ; 144.7 (CN) ; 139.8 (C₈) ; 133.4 (C_{Ar}) ; 127.2 (C_{Ar}) ; 119.2 (C₅) ; 117.7 (C_q Ar) ; 114.9 (C_q Ar) ; 87.4 (C_{1'}) ; 83.8 (C_{4'}) ; 72.6 (C_{3'}) ; 72.5 (C_{2'}) ; 42.6 (CH₂ Et) ; 33.8 (C_{5'}) ; 31.6 (CH₂ Et). **HRMS** (ESI+): m/z calc. for C₁₉H₂₂N₇O₅S₂ [M+H]⁺: 492.1124, Found 492.1137.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-methylbenzene-

sulfonamide (4). Following method C with intermediate 36 (150 mg, 0.29 mmol, 1.00 eq), 4 was obtained as a white solid (96 mg, 69%). R_f 0.16 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈)

; 8.14 (s, 1H, H₂); 7.66 – 7.63 (m, 2H, H_{Ar}); 7.37 (m, 2H, H_{Ar}); 7.27 (s, 2H, NH₂); 5.87 (d, J = 5.7 Hz, 1H, H_{1'}); 5.48 (s, 1H, OH_{2'}); 5.29 (s, 1H, OH_{3'}); 4.71 (m, 1H, H_{2'}); 4.12 – 4.09 (m, 1H, H_{3'}); 3.94 (m, 1H, H_{4'}); 2.87 (m, 3H, CH_{2 Et}, H_{5'}); 2.78 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}); 2.53 (m, 2H, CH_{2 Et}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.4 (C₄); 142.6 (C_{q Ar}); 139.8 (C₈); 137.6 (C_{q Ar}); 129.6 (C_{Ar}); 126.5 (C_{Ar}); 119.2 (C₅); 87.4 (C_{1'}); 83.7 (C_{4'}); 72.6 (C_{2'}); 72.5 (C_{3'}); 42.7 (CH_{2 Et}); 33.9 (C_{5'}); 31.5 (CH_{2 Et}); 20.9 (CH_{3 Ar}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₅N₆O₅S₂ [M+H]⁺: 481.1328, Found 481.1335.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-(trifluoromethyl)-benzenesulfonamide (5). Following method C with intermediate 37 (115 mg, 0.20 mmol, 1.00 eq), 5 was obtained as a white solid (68 mg, 64%). R_f 0.19 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈); 8.14 (s, 1H, H₂); 8.05 (br s, 1H, NH); 8.00 – 7.95 (m, 4H, H_{Ar}); 7.27 (s, 2H, NH₂); 5.87 (d, J = 5.7 Hz, 1H, H_{1'}); 5.49 (d, J = 6.0 Hz, 1H, OH_{2'}); 5.29 (d, J = 4.6 Hz, 1H, OH_{3'}); 4.71 (q, J = 5.5 Hz, 1H, H_{2'}); 4.14 – 4.09 (m, 1H, H_{3'}); 3.95 (m, 1H, H_{4'}); 2.95 (t, J = 6.6 Hz, 2H, CH_{2 Et}); 2.88 (dd, J = 13.8, 5.7 Hz, 1H, H_{5'}); 2.80 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}); 2.60 – 2.51 (m, 2H, CH_{2 Et}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.4 (C₄); 144.5 (C_{q Ar}); 139.8 (C₈); 132.5, 132.3, 132.0, 131.8 (C_{q Ar}); 127.4 (C_{Ar}); 126.5 (C_{Ar}); 126.2, 124.4, 122.6, 120.8 (CF₃); 119.2 (C₅); 87.4 (C_{1'}); 83.8 (C_{4'}); 72.6 (C_{2'}); 72.5 (C_{3'}); 42.7 (CH_{2 Et}); 33.9 (C_{5'}); 31.6 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₂F₃N₆O₅S₂ [M+H]⁺: 535.1040, Found 535.1041.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-2-nitrobenzene-

sulfonamide (6). Following method C with intermediate 38 (117 mg, 0.21 mmol, 1.00 eq), 6 (83 mg, 77%) was obtained as a white solid (83 mg, 77%). R_f 0.14 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (500 MHz, DMSO- d_6) δ 8.33 (s, 1H, H₈); 8.20 (br s, 1H, NH); 8.14 (s, 1H, H₂); 8.00 – 7.94 (m, 2H, H_{Ar}); 7.84 (m, 2H, H_{Ar}); 7.31 (s, 2H, NH₂); 5.87 (d, J = 5.8 Hz, 1H, H_{1'}); 5.52 (d, J = 6.1 Hz, 1H, OH_{2'}); 5.33 (d, J = 5.0 Hz, 1H, OH_{3'}); 4.71 (q, J = 5.7 Hz, 1H, H_{2'}); 4.10 (dd, J = 8.7, 4.7 Hz, 1H, H_{3'}); 3.95 (m, 1H, H_{4'}); 3.07 (m, 2H, CH_{2 Et}); 2.88 (dd, J = 13.8, 5.8 Hz, 1H, H_{5'}); 2.80 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}); 2.58 (m, 2H, CH_{2 Et}). $^{13}\text{C-NMR}$ (126 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 149.5 (C₄); 147.6 (C_{q Ar}); 139.9 (C₈); 134.1 (C_{Ar}); 132.9 (C_{q Ar}); 132.8 (C_{Ar}); 129.5 (C_{Ar}); 124.5 (C_{Ar}); 119.2 (C₅); 87.4 (C_{1'}); 83.8 (C_{4'}); 72.6 (C_{2'}); 72.6 (C_{3'}); 42.8 (CH_{2 Et}); 33.8 (C_{5'}); 31.6 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₈H₂₂N₇O₇S₂ [M+H]⁺: 512.1017, Found 512.1018.




N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-methoxy-2-nitrobenzenesulfonamide (7).

Following method C with intermediate 39 (92 mg, 0.16 mmol, 1.00 eq), 7 was obtained as a white solid (79 mg, 92%). R_f 0.15 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (500 MHz, DMSO- d_6) δ 8.33 (s, 1H, H₈); 8.14 (s, 1H, H₂), 8.00 (br s, 1H, NH); 7.87 (m, 1H, H_{Ar}); 7.56 (m, 1H, H_{Ar}); 7.34 (dd, J = 8.9, 2.6 Hz, 1H, H_{Ar}); 7.31 (br s, 2H, NH₂); 5.87 (d, J = 5.8 Hz, 1H, H_{1'}); 5.53 (d, J = 6.1 Hz, 1H, OH_{2'}); 5.34 (d, J = 4.9 Hz, 1H, OH_{3'}); 4.72 (dd, J = 11.1, 5.7 Hz, 1H, H_{2'}); 4.11 (dd, J = 8.6, 4.7 Hz, 1H, H_{3'}); 3.97 – 3.92 (m, 1H, H_{4'}); 3.89 (s, 3H, OCH₃); 3.03 (t, J = 7.2 Hz, 2H, CH_{2 Et}); 2.88 (dd, J = 13.7, 5.9 Hz, 1H, H_{5'}); 2.80 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}); 2.57 (m, 2H, CH_{2 Et}). $^{13}\text{C-NMR}$ (126 MHz, DMSO- d_6) δ 162.6 (C_{q Ar}); 156.1 (C₆); 152.7 (C₂); 149.5 (C₄); 149.1 (C_{q Ar}); 139.9 (C₈); 131.3 (C_{Ar}); 124.1 (C_{q Ar}); 119.2 (C₅); 117.5 (C_{Ar}); 109.9 (C_{Ar}); 87.4 (C_{1'}); 83.8 (C_{4'}); 72.6 (C_{3'}); 72.6 (C_{2'}); 56.7 (OCH₃); 42.7 (CH_{2 Et}); 33.8 (C_{5'}); 31.5 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₄N₇O₈S₂ [M+H]⁺: 542.1122, Found 542.1126.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)thio)ethyl)-4-chloro-2-nitrobenzenesulfonamide (8).


Following method C with intermediate 40 (75 mg, 0.13 mmol, 1.00 eq), 8 was obtained as a white solid (57 mg, 82%). R_f 0.1 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈); 8.29 (br s, 1H, NH); 8.23 (d, J = 2.1 Hz, 1H, H_{Ar}); 8.14 (s, 1H, H₂); 7.97 (d, J = 8.6 Hz 1H, H_{Ar}); 7.93 (dd, J = 8.6, 2.1 Hz, 1H, H_{Ar}); 7.26 (br s, 2H, NH₂); 5.87 (d, J = 5.6 Hz, 1H, H_{1'}); 5.49 (d, J = 6.0 Hz, 1H, OH_{2'}); 5.30 (m, 1H, OH_{3'}); 4.71 (dd, J = 10.9, 5.5 Hz, 1H, H_{2'}); 4.11 (m, 1H, H_{3'}); 3.97 – 3.94 (m, 1H, H_{4'}); 3.08 (t, J = 7.2 Hz, 2H, CH_{2 Et}); 2.88 (dd, J = 13.8, 5.7 Hz, 1H, H_{5'}); 2.81 (dd, J = 13.8, 7.1 Hz, 1H, H_{5''}); 2.59 (m, 2H, CH_{2 Et}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 149.4 (C₄); 148.0 (C_{q Ar}); 139.8 (C₈); 138.1 (C_{q Ar}); 132.6 (C_{Ar}); 131.7 (C_{Ar}); 131.1 (C_{Ar}); 124.4 (C_{q Ar}); 119.2 (C₅); 87.4 (C_{1'}); 83.8 (C_{4'}); 72.6 (C_{3'}); 72.5 (C_{2'}); 42.7 (CH_{2 Et}); 33.8 (C_{5'}); 31.6 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₈H₂₁ClN₇O₇S₂ [M+H]⁺: 546.0627, Found 546.0626.



Synthesis of N-arylsulfonamide adenosine analogues with an N-ethylsulfone linker (41-45 ; 9-13)

N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfonyl)ethyl)-

benzenesulfonamide (41). Following method B with intermediate 33 (135 mg, 0.27 mmol, 1.00 eq) and mCPBA (161 mg, 0.93 mmol, 3.50 eq), 41 was obtained as a white solid (119 mg, 83%). R_f 0.26 (5:95 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.32 (s, 1H, H₈); 8.18 (s, 1H, H₂); 7.82 (br s, 1H, NH); 7.74 – 7.71 (m, 2H, H_{Ar}); 7.64 (m, 1H, H_{Ar}); 7.61 – 7.57 (m, 2H, H_{Ar}); 7.37 (br s, 2H, NH₂); 6.24 (d, J = 2.2 Hz, 1H, H_{1'}); 5.39 (dd, J = 6.2, 2.2 Hz, 1H, H_{2'}); 5.12 (dd, J = 6.2, 3.2 Hz, 1H, H_{3'}); 4.53 (m, 1H, H_{4'}); 3.74 (dd, J = 14.7, 5.0 Hz, 1H, H_{5'}); 3.69 (dd, J = 14.7, 7.9 Hz, 1H, H_{5''}); 3.11 (t, J = 7.2 Hz, 2H, CH_{2 Et}); 3.01 (m, 2H, CH_{2 Et}); 1.55 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.2 (C₆); 152.8 (C₂); 148.5 (C₄); 140.1 (C₈); 139.6 (C_{q Ar}); 132.7 (C_{Ar}); 129.3 (C_{Ar}); 126.4 (C_{Ar}); 119.3 (C₅); 113.6 (C_{q isopr}); 89.3 (C_{1'}); 83.5 (C_{3'}).




; 83.3 (C_{2'}); 80.6 (C_{4'}); 55.6 (C_{5'}); 52.9 (CH_{2 Et}); 35.8 (CH_{2 Et}); 26.9 (CH_{3 isopr}); 25.2 (CH_{3 isopr}). **HRMS** (ESI⁺): m/z calc. for C₂₁H₂₇N₆O₇S₂ [M+H]⁺: 539.1377, Found 539.1377.

N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfonyl)ethyl)-4-nitrobenzenesulfonamide (42). Following method **B** with

intermediate **34** (138 mg, 0.25 mmol, 1.00 eq) and mCPBA (151 mg, 0.88 mmol, 3.50 eq), **42** was obtained as a white solid (105 mg, 72%).

R_f 0.43 (5:95 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.43 – 8.39 (m, 2H, H_{Ar}); 8.32 (s, 1H, H₈); 8.24 (br s, 1H, NH); 8.18 (s, 1H,

H₂); 8.00 – 7.96 (m, 2H, H_{Ar}); 7.37 (s, 2H, NH₂); 6.24 (d, *J* = 2.1 Hz, 1H, H_{1'}); 5.40 (dd, *J* = 6.2, 2.2 Hz, 1H, H_{2'}); 5.11 (dd, *J* = 6.2, 3.1 Hz, 1H, H_{3'}); 4.52 (m, 1H, H_{4'}); 3.77 – 3.67 (m, 2H, H_{5'}); 3.14 (t, *J* = 7.1 Hz, 2H, CH_{2 Et}); 3.09 – 3.04 (m, 2H, CH_{2 Et}); 1.54 (s, 3H, CH_{3 isopr}); 1.33 (s, 3H, CH_{3 isopr}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.2 (C₆); 152.8 (C₂); 149.7 (C_{q Ar}); 148.5 (C₄); 145.3 (C_{q Ar}); 140.1 (C₈); 128.1 (C_{Ar}); 124.7 (C_{Ar}); 119.3 (C₅); 113.6 (C_{q isopr}); 89.3 (C_{1'}); 83.5 (C_{3'}); 83.2 (C_{2'}); 80.6 (C_{4'}); 55.6 (C_{5'}); 53.0 (CH_{2 Et}); 35.8 (CH_{2 Et}); 26.9 (CH_{3 isopr}); 25.1 (CH_{3 isopr}). **HRMS** (ESI⁺): m/z calc. for C₂₁H₂₆N₇O₉S₂ [M+H]⁺: 584.1228, Found 584.1233.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfonyl)ethyl)-4-cyanobenzenesulfonamide (43). Following method **B** with

intermediate **35** (123 mg, 0.23 mmol, 1.00 eq) and mCPBA (140 mg, 0.81 mmol, 3.50 eq), **43** was obtained as a white solid (67 mg, 51%).

R_f 0.46 (5:95 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.32 (s, 1H, H₈); 8.18 (s, 1H, H₂); 8.10 – 8.07 (m, 2H, H_{Ar}); 7.90 – 7.86 (m, 2H,

H_{Ar}); 7.38 (br s, 2H, NH₂); 6.25 (d, *J* = 2.2 Hz, 1H, H_{1'}); 5.40 (dd, *J* = 6.1, 2.3 Hz, 1H, H_{2'}); 5.12 (dd, *J* = 6.2, 3.1 Hz, 1H, H_{3'}); 4.51 – 4.54 (m, 1H, H_{4'}); 3.76 – 3.68 (m, 2H, H_{5'}); 3.16 – 3.11 (m, 2H, CH_{2 Et}); 3.06 – 3.00 (m, 2H, CH_{2 Et}); 1.55 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.2 (C₆); 152.8 (C₂); 148.5 (C₄); 143.9 (CN); 140.1 (C₈); 133.5 (C_{Ar}); 127.2 (C_{Ar}); 119.3 (C₅); 117.7 (C_{q Ar}); 115.1 (C_{q Ar}); 113.6 (C_{q isopr}); 89.4 (C_{1'}); 83.5 (C_{3'}); 83.2 (C_{2'}); 80.7 (C_{4'}); 54.9 (C_{5'}); 53.0 (CH_{2 Et}); 35.8 (CH_{2 Et}); 26.9 (CH_{3 isopr}); 25.2 (CH_{3 isopr}). **HRMS** (ESI⁺): m/z calc. for C₂₂H₂₆N₇O₇S₂ [M+H]⁺: 564.1330, Found 564.1325.




N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfonyl)ethyl)-4-methylbenzenesulfonamide (44). Following method **B** with

intermediate **36** (120 mg, 0.23 mmol, 1.00 eq) and mCPBA (139 mg, 0.81 mmol, 3.50 eq), **44** was obtained as a white solid (78 mg, 61%).

R_f 0.42 (5:95 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.33 (s, 1H, H₈); 8.17 (s, 1H, H₂); 7.73 (br s, 1H, NH); 7.60 (m, 2H, H_{Ar}); 7.40 – 7.37

(m, 4H, H_{Ar}, NH₂); 6.24 (d, *J* = 2.2 Hz, 1H, H_{1'}); 5.39 (dd, *J* = 6.1, 2.2 Hz, 1H, H_{2'}); 5.12 (dd, *J* = 6.2, 3.1 Hz, 1H, H_{3'}); 4.52 (m, 1H, H_{4'}); 3.74 (dd, *J* = 14.7, 5.0 Hz, 1H, H_{5'}); 3.69 (dd, *J* = 14.6, 7.9 Hz, 1H, H_{5''}); 3.11 (t, *J* = 7.2 Hz, 2H, CH_{2 Et}); 3.00 – 2.95 (m, 2H, CH_{2 Et}); 2.38 (s, 3H, CH_{3 Ar}); 1.55 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.2 (C₆); 152.8 (C₂); 148.5 (C₄); 143.0 (C_{q Ar}); 140.1 (C₈); 136.7 (C_{q Ar}); 129.8 (C_{Ar}); 126.6 (C_{Ar}); 119.3 (C₅); 113.6 (C_{q isopr}); 89.3 (C_{1'}); 83.5 (C_{3'}); 83.3 (C_{2'});




80.6 (C_{4'}) ; 55.6 (C_{5'}) ; 52.9 (CH_{2 Et}) ; 35.8 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.2 (CH_{3 isopr}) ; 21.0 (CH_{3 Ar}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₉N₆O₇S₂ [M+H]⁺: 553.1534, Found 553.1545.

N-(2-((((3aS,4S,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfonyl)ethyl)-4-(trifluoromethyl)benzenesulfonamide (45).

Following method **B** with intermediate **37** (157 mg, 0.27 mmol, 1.00 eq) and mCPBA (165 mg, 0.96 mmol, 3.50 eq), **45** was obtained as a white solid (118 mg, 71%). R_f 0.41 (5:95 MeOH/DCM).


¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.32 (s, 1H, H₈) ; 8.18 (s, 1H, H₂) ; 8.12 (br s, 1H, NH) ; 8.00 – 7.98 (m, 2H, H_{Ar}) ; 7.95 – 7.93 (m, 2H, H_{Ar}) ; 7.37 (br s, 2H, NH₂) ; 6.25 (d, *J* = 2.2 Hz, 1H, H_{1'}) ; 5.40 (dd, *J* = 6.2, 2.2 Hz, 1H, H_{2'}) ; 5.12 (dd, *J* = 6.2, 3.1 Hz, 1H, H_{3'}) ; 4.53 (m, 1H, H_{4'}) ; 3.75 (dd, *J* = 14.7, 5.0 Hz, 1H, H_{5'}) ; 3.70 (dd, *J* = 14.7, 7.9 Hz, 1H, H_{5''}) ; 3.14 (t, *J* = 7.2 Hz, 2H, CH_{2 Et}) ; 3.07 – 3.03 (m, 2H, CH_{2 Et}) ; 1.54 (s, 3H, CH_{3 isopr}) ; 1.32 (s, 3H, CH_{3 isopr}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.2 (C₆) ; 152.8 (C₂) ; 148.5 (C₄) ; 143.7 (C_{q Ar}) ; 140.1 (C₈) ; 132.7, 132.5, 132.3, 132.1 (C_{q Ar}) ; 127.5 (C_{Ar}) ; 126.6 (C_{Ar}) ; 126.2, 124.4, 122.6, 120.8 (CF₃) ; 119.3 (C₅) ; 113.6 (C_{q isopr}) ; 89.3 (C_{1'}) ; 83.5 (C_{3'}) ; 83.3 (C_{2'}) ; 80.6 (C_{4'}) ; 55.6 (C_{5'}) ; 53.0 (CH_{2 Et}) ; 35.8 (CH_{2 Et}) ; 26.9 (CH_{3 isopr}) ; 25.1 (CH_{3 isopr}). **HRMS** (ESI+): m/z calc. for C₂₂H₂₆F₃N₆O₇S₂ [M+H]⁺: 607.1251, Found 607.1234.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)benzenesulfonamide (9).

Following method **C** with intermediate **41** (135 mg, 0.27 mmol, 1.00 eq), **9** was obtained as a white solid (119 mg, 83%). R_f 0.09 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.35 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 7.82 (t, *J* = 5.1 Hz, 1H, NH) ; 7.71 – 7.68 (m, 2H, H_{Ar}) ; 7.64 – 7.60 (m, 1H, H_{Ar}) ; 7.58 – 7.54 (m, 2H, H_{Ar}) ; 7.31 (br s, 2H, NH₂) ; 5.92


(d, *J* = 5.4 Hz, 1H, H_{1'}) ; 5.60 (d, *J* = 5.8 Hz, 1H, OH_{2'}) ; 5.53 (d, *J* = 5.0 Hz, 1H, OH_{3'}) ; 4.65 (dd, *J* = 10.5, 5.3 Hz, 1H, H_{2'}) ; 4.31 – 4.26 (m, 1H, H_{4'}) ; 4.21 (dd, *J* = 9.0, 4.6 Hz, 1H, H_{3'}) ; 3.95 (dd, *J* = 14.9, 9.4 Hz, 1H, H_{5'}) ; 3.52 (dd, *J* = 14.9, 2.8 Hz, 1H, H_{5''}) ; 3.20 – 3.13 (m, 1H, CH_{2 Et}) ; 3.12 – 3.05 (m, 3H, CH_{2 Et}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.1 (C₄) ; 140.0 (C₈) ; 139.7 (C_{q Ar}) ; 132.6 (C_{Ar}) ; 129.3 (C_{Ar}) ; 126.4 (C_{Ar}) ; 119.4 (C₅) ; 88.2 (C_{1'}) ; 78.3 (C_{4'}) ; 73.0 (C_{3'}) ; 72.4 (C_{2'}) ; 56.1 (C_{5'}) ; 53.0 (CH_{2 Et}) ; 35.7 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₈H₂₃N₆O₇S₂ [M+H]⁺: 499.1064, Found 499.1063.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)-4-nitrobenzenesulfonamide (10).

Following method **C** with intermediate **42** (100 mg, 0.17 mmol, 1.00 eq), **10** was obtained as a white solid (64 mg, 69%). R_f 0.09 (1:9 MeOH/DCM).


¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.42 – 8.38 (m, 2H, H_{Ar}) ; 8.34 (s, 1H, H₈) ; 8.23 (t, *J* = 5.3 Hz, 1H, NH) ; 8.15 (s, 1H, H₂) ; 7.97 – 7.94 (m, 2H, H_{Ar}) ; 7.30 (br s, 2H, NH₂) ; 5.92 (d, *J* = 5.4 Hz, 1H, H_{1'}) ; 5.60 (d, *J* = 5.9 Hz, 1H, OH_{2'}) ; 5.52 (d, *J* = 5.0 Hz, 1H, OH_{3'}) ; 4.66 (dd, *J* = 10.6, 5.5 Hz, 1H, H_{2'}) ; 4.29 (ddd, *J* = 9.4, 3.8, 2.9 Hz, 1H, H_{4'}) ; 4.21 (dd, *J* = 9.1, 4.7 Hz, 1H, H_{3'}) ; 3.96 (dd, *J* = 14.9, 9.4 Hz, 1H, H_{5'}) ; 3.53 (dd, *J* = 14.9, 2.7 Hz, 1H, H_{5''}) ; 3.24 – 3.18 (m, 1H, CH_{2 Et}) ; 3.17 – 3.11 (m, 3H, CH_{2 Et}). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.7 (C_{q Ar}) ; 149.1 (C₄) ; 145.4 (C_{q Ar}) ; 140.0 (C₈) ; 128.1 (C_{Ar}) ; 124.7 (C_{Ar}) ; 119.4 (C₅) ; 88.2 (C_{1'}) ; 78.3 (C_{4'}) ; 73.0 (C_{3'}) ; 72.4 (C_{2'}) ; 56.2 (C_{5'}) ; 53.1 (CH_{2 Et}) ; 35.7 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₈H₂₂N₇O₉S₂ [M+H]⁺: 544.0915, Found 544.0912.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)-4-cyanobenzene-sulfonamide (11).

Following method C with intermediate 43 (67 mg, 0.12 mmol, 1.00 eq), 11 was obtained as a white solid (53 mg, 85%). R_f 0.10 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.35 (s, 1H, H₈); 8.18 – 8.14 (m, 2H, NH, H₂); 8.09 – 8.05 (m, 2H, H_{Ar}); 7.88 – 7.84 (m, 2H, H_{Ar}); 7.32 (br s, 2H, NH₂); 5.93 (d, J = 5.4 Hz, 1H, H_{1'}); 5.60 (d, J = 5.9 Hz, 1H, OH_{2'}); 5.53 (d, J = 5.0 Hz, 1H, OH_{3'}); 4.66 (dd,


J = 10.6, 5.5 Hz, 1H, H_{2'}); 4.29 (ddd, J = 9.4, 3.8, 2.9 Hz, 1H, H_{4'}); 4.22 (dd, J = 9.1, 4.7 Hz, 1H, H_{3'}); 3.97 (dd, J = 14.9, 9.4 Hz, 1H, H_{5'}); 3.53 (dd, J = 14.9, 2.7 Hz, 1H, H_{5''}); 3.20 (m, 1H, CH_{2 Et}); 3.15 – 3.08 (m, 3H, CH_{2 Et}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.1 (C₄); 143.9 (CN); 140.1 (C₈); 133.5 (C_{Ar}); 127.2 (C_{Ar}); 119.4 (C₅); 117.7 (C_{q Ar}); 115.1 (C_{q Ar}); 88.2 (C_{1'}); 78.3 (C_{4'}); 73.0 (C_{3'}); 72.4 (C_{2'}); 56.1 (C_{5'}); 53.1 (CH_{2 Et}); 35.7 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₂N₇O₇S₂ [M+H]⁺: 524.1017, Found 524.1011.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)-4-methylbenzene-sulfonamide (12).

Following method C with intermediate 44 (72 mg, 0.13 mmol, 1.00 eq), 12 was obtained as a white solid (44 mg, 66%). R_f 0.11 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.35 (s, 1H, H₈); 8.16 (s, 1H, H₂); 7.72 (br s, 1H, NH); 7.59 – 7.56 (m, 2H, H_{Ar}); 7.36 (m, 2H, H_{Ar}); 7.31 (br s, 2H, NH₂); 5.92 (d, J = 5.3 Hz, 1H, H_{1'}); 5.60 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.53 (d, J = 4.8 Hz, 1H,


OH_{3'}); 4.65 (q, J = 5.2 Hz, 1H, H_{2'}); 4.31 – 4.27 (m, 1H, H_{4'}); 4.21 (q, J = 4.3 Hz, 1H, H_{3'}); 3.95 (dd, J = 14.8, 9.3 Hz, 1H, H_{5'}); 3.52 (dd, J = 14.8, 2.7 Hz, 1H, H_{5''}); 3.21 – 3.07 (m, 2H, CH_{2 Et}); 3.06 – 3.01 (m, 2H, CH_{2 Et}); 2.37 (s, 3H, CH_{3 Ar}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.1 (C₄); 143.0 (C_{q Ar}); 140.0 (C₈); 136.8 (C_{q Ar}); 129.7 (C_{Ar}); 126.5 (C_{Ar}); 119.4 (C₅); 88.2 (C_{1'}); 78.2 (C_{4'}); 73.0 (C_{3'}); 72.4 (C_{2'}); 56.1 (C_{5'}); 53.0 (CH_{2 Et}); 35.7 (CH_{2 Et}); 21.0 (CH_{3 Ar}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₅N₆O₇S₂ [M+H]⁺: 513.1221, Found 513.1216.



N-(2-((((2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)sulfonyl)ethyl)-4-(trifluoromethyl)benzenesulfonamide (13).


Following method C with intermediate 45 (107 mg, 0.18 mmol, 1.00 eq), 13 was obtained as a white solid (77 mg, 77%). R_f 0.08 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.36 (s, 1H, H₈); 8.16 (s, 1H, H₂); 8.13 (br s, 1H, NH); 7.97 (d, J = 8.4 Hz, 2H, H_{Ar}); 7.92 (d, J = 8.3 Hz, 2H, H_{Ar}); 7.31 (br s, 2H, NH₂); 5.93

(d, J = 5.4 Hz, 1H, H_{1'}); 5.61 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.53 (d, J = 3.4 Hz, 1H, OH_{3'}); 4.66 (q, J = 5.2 Hz, 1H, H_{2'}); 4.32 – 4.28 (m, 1H, H_{4'}); 4.22 (d, J = 3.1 Hz, 1H, H_{3'}); 3.96 (dd, J = 14.9, 9.4 Hz, 1H, H_{5'}); 3.54 (dd, J = 14.9, 2.8 Hz, 1H, H_{5''}); 3.22 (m, 1H, CH_{2 Et}); 3.18 – 3.09 (m, 3H, CH_{2 Et}). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.1 (C₄); 143.7 (C_{q Ar}); 140.0 (C₈); 132.7, 132.5, 132.3, 132.1 (CF₃); 127.5 (C_{Ar}); 126.6 (C_{Ar}); 126.2, 124.4, 122.6, 120.8 (C_{q Ar}); 119.4 (C₅); 88.2 (C_{1'}); 78.3 (C_{4'}); 73.0 (C_{3'}); 72.4 (C_{2'}); 56.1 (C_{5'}); 53.1 (CH_{2 Et}); 35.7 (CH_{2 Et}). **HRMS** (ESI+): m/z calc. for C₁₉H₂₂F₃N₆O₇S₂ [M+H]⁺: 567.0938, Found 567.0945.




Synthesis of *N*-arylsulfonamide adenosine analogues with an *N*-ethylamino linker (46-53 ; 14-18)

2-(2-((((3*a*R,4*R*,6*R*,6*a*R)-6-(6-amino-9*H*-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl)amino)ethyl)-isoindoline-1,3-dione (46). NaBH(OAc)₃ (6.00 g, 28.4 mmol, 8.70 eq) was slowly added to a solution under argon of 5'-amino-2',3'-*O*-isopropylideneadenosine (1.00 g, 3.26 mmol, 1.00 eq) and *N*-(2-oxoethyl)phthalimide (710 mg, 3.75 mmol, 1.15 eq) in anhydrous THF (0.12M). After stirring at r.t for 18 h, the reaction mixture was filtered



twice through celite and concentrated under vacuum. The residue was purified by flash column chromatography (dry sample, silica gel, linear gradient 0-8% MeOH in DCM) to give **46** as a white solid (816 mg, 52%). R_f 0.55 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.32 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 7.85 – 7.79 (m, 4H, H_{Ar}) ; 7.30 (br s, 2H, NH₂) ; 6.04 (d, *J* = 3.3 Hz, 1H, H_{1'}) ; 5.35 (dd, *J* = 6.3, 3.3 Hz, 1H, H_{2'}) ; 4.88 (dd, *J* = 6.3, 2.7 Hz, 1H, H_{3'}) ; 4.14 (td, *J* = 5.9, 2.7 Hz, 1H, H_{4'}) ; 3.66 – 3.58 (m, 2H, CH₂ Et) ; 2.75 (m, 3H, H_{5'}, CH₂ Et) ; 2.68 (dd, *J* = 12.3, 5.8 Hz, 1H, H_{5''}) ; 1.90 (s, 1H) ; 1.50 (s, 3H, CH₃ isopr) ; 1.25 (s, 3H, CH₃ isopr). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 168.0 (CO) ; 156.1 (C₆) ; 152.7 (C₂) ; 148.9 (C₄) ; 139.8 (C₈) ; 134.2 (C_{Ar}) ; 131.7 (C_q Ar) ; 122.9 (C_{Ar}) ; 119.2 (C₅) ; 113.1 (C_q isopr) ; 89.1 (C_{1'}) ; 84.8 (C_{4'}) ; 82.6 (C_{2'}) ; 82.1 (C_{3'}) ; 50.2 (C_{5'}) ; 46.7 (CH₂ Et) ; 37.3 (CH₂ Et) ; 27.0 (CH₃ isopr) ; 25.1 (CH₃ isopr). HRMS (ESI+): *m/z* calc. for C₂₃H₂₆N₇O₅ [M+H]⁺: 480.1990, Found 480.1990.


2-(2-((((3*a*R,4*R*,6*R*,6*a*R)-6-(6-amino-9*H*-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl)(ethyl)amino)ethyl)-isoindoline-1,3-dione (47). Acetic acid (179 mg, 2.99 mmol, 1.80 eq) was added to a solution under argon of **46** (796 mg, 1.66 mmol, 1.00 eq) and ethanal (132 mg, 2.99 mmol, 1.80 eq) in anhydrous DCE (0.017 M). After stirring at r.t for 20 min, NaBH(OAc)₃ (792 mg, 3.74 mmol, 2.25 eq) was added. After stirring at r.t for 18 h, the reaction mixture was diluted with



DCM and saturated NaHCO₃. The aqueous layer was extracted with DCM and the combined organic extracts were washed with brine, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash column chromatography (silica gel, linear gradient 0-4% MeOH in DCM) to give **47** as a white solid (611 mg, 1.20 mmol, 72.5%). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.24 (s, 1H, H₈) ; 8.15 (s, 1H, H₂) ; 7.86 – 7.80 (m, 4H, H_{Ar}) ; 7.30 (br s, 2H, NH₂) ; 6.00 (d, *J* = 2.3 Hz, 1H, H_{1'}) ; 5.37 (dd, *J* = 6.3, 2.3 Hz, 1H, H_{2'}) ; 4.79 (dd, *J* = 6.3, 2.7 Hz, 1H, H_{3'}) ; 4.00 (ddd, *J* = 8.6, 6.1, 2.7 Hz, 1H, H_{4'}) ; 3.69 (ddd, *J* = 14.0, 8.2, 5.8 Hz, 1H, CH₂ Et) ; 3.54 (dt, *J* = 14.0, 5.5 Hz, 1H, CH₂ Et) ; 2.74 – 2.63 (m, 2H, CH₂ Et) ; 2.61 – 2.55 (m, 2H, CH₂ Et, H_{5'}) ; 2.45 – 2.37 (m, 2H, H_a, H_{5''}) ; 1.32 (s, 3H, CH₃ isopr) ; 1.05 (s, 3H, CH₃ isopr) ; 0.88 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 168.0 (CO) ; 156.1 (C₆) ; 152.6 (C₂) ; 148.6 (C₄) ; 140.1 (C₈) ; 134.1 (C_{Ar}) ; 131.8 (C_q Ar) ; 122.9 (C_{Ar}) ; 119.2 (C₅) ; 112.7 (C_q isopr) ; 89.4 (C_{1'}) ; 84.6 (C_{4'}) ; 82.9 (C_{3'}) ; 82.7 (C_{2'}) ; 54.9 (C_{5'}) ; 50.7 (CH₂ Et) ; 47.2 (C_a) ; 35.7 (CH₂ Et) ; 26.7 (CH₃ isopr) ; 24.8 (CH₃ isopr) ; 11.5 (C_b). HRMS (ESI+): *m/z* calc. for C₂₅H₃₀N₇O₅ [M+H]⁺: 508.2303, Found 508.2301.

N1-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)-N1-ethylethane-1,2-diamine (48).


Compound **47** (600 mg, 1.18 mmol, 1eq) was dissolved in a solution of methylamine in EtOH (33%, 20 mL) and stirred at r.t overnight. After concentration under vacuum, the residue was dissolved in CHCl₃ and extracted with 10% aqueous CH₃COOH. The aqueous layer was washed with CHCl₃ (3x) and pH was adjusted to > 12 using NaOH (2N) and then extracted



with CHCl₃ (4x). The final organic layers were dried over Na₂SO₄ and concentrated under vacuum to give **48** as a white solid (407 mg, 91%). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.33 (s, 1H, H₈) ; 8.16 (s, 1H, H₂) ; 7.31 (br s, 2H, NH₂) ; 6.14 (d, *J* = 2.3 Hz, 1H, H_{1'}) ; 5.49 (dd, *J* = 6.3, 2.3 Hz, 1H, H_{2'}) ; 4.97 (dd, *J* = 6.3, 3.0 Hz, 1H, H_{3'}) ; 4.19 (td, *J* = 7.4, 2.9 Hz, 1H, H_{4'}) ; 2.64 (dd, *J* = 13.3, 7.6 Hz, 1H, H_{5'}) ; 2.49 – 2.40 (m, 5H, H_{5''}, H_a, CH₂ Et) ; 2.36 (m, 2H, CH₂ Et) ; 1.52 (s, 3H, CH₃ isopr) ; 1.33 (s, 3H, CH₃ isopr) ; 0.87 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.8 (C₄) ; 140.1 (C₈) ; 119.2 (C₅) ; 113.0 (C_q isopr) ; 89.1 (C_{1'}) ; 84.8 (C_{4'}) ; 83.0 (C_{3'}) ; 83.0 (C_{2'}) ; 57.1 (CH₂ Et) ; 55.4 (C_{5'}) ; 47.9 (C_a) ; 39.7 (CH₂ Et) ; 27.0 (CH₃ isopr) ; 25.2 (CH₃ isopr) ; 11.5 (C_b). HRMS (ESI+): *m/z* calc. for C₁₇H₂₈N₇O₃ [M+H]⁺: 378.2248, Found 378.2245.

N-(2-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(ethylamino)ethyl)-benzenesulfonamide (49).


Following method A with **48** (130 mg, 0.34 mmol, 1.00 eq) and benzenesulfonyl chloride (76 mg, 0.43 mmol, 1.25 eq), **49** was obtained as a white solid (117 mg, 66%). R_f 0.42 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.30 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 7.79 – 7.76 (m, 2H, H_{Ar}) ; 7.65 – 7.61 (m, 1H, H_{Ar}) ; 7.60 –



7.56 (m, 2H, H_{Ar}) ; 7.37 (m, 1H, NH) ; 7.32 (br s, 2H, NH₂) ; 6.13 (s, 1H, H_{1'}) ; 5.44 (dd, *J* = 6.3, 2.2 Hz, 1H, H_{2'}) ; 4.92 (d, *J* = 3.0 Hz, 1H, H_{3'}) ; 4.11 (s, 1H, H_{4'}) ; 2.77 (d, *J* = 6.1 Hz, 2H, CH₂ Et) ; 2.65 – 2.59 (m, 1H, H_{5'}) ; 2.48 – 2.30 (m, 5H, H_{5''}, H_a, CH₂ Et) ; 1.53 (s, 3H, CH₃ isopr) ; 1.32 (s, 3H, CH₃ isopr) ; 0.78 (t, *J* = 6.9 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.7 (C₂) ; 148.7 (C₄) ; 140.4 (C_q Ar) ; 140.1 (C₈) ; 132.3 (C_{Ar}) ; 129.2 (C_{Ar}) ; 126.4 (C_{Ar}) ; 119.2 (C₅) ; 113.2 (C_q isopr) ; 89.1 (C_{1'}) ; 84.4 (C_{4'}) ; 83.0 (C_{2'}) ; 82.8 (C_{3'}) ; 55.0 (C_{5'}) ; 52.5 (CH₂ Et) ; 47.7 (C_a) ; 40.7 (CH₂ Et) ; 27.0 (CH₃ isopr) ; 25.2 (CH₃ isopr) ; 11.4 (C_b). HRMS (ESI+): *m/z* calc. for C₂₃H₃₂N₇O₅S [M+H]⁺: 518.2180, Found 518.2181.

N-(2-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(ethylamino)ethyl)-4-nitrobenzenesulfonamide (50).


Following method A with **48** (110 mg, 0.29 mmol, 1.00 eq) and 4-nitrobenzenesulfonyl chloride (81 mg, 0.36 mmol, 1.25 eq), **50** was obtained as a white solid (79 mg, 48%). R_f 0.63 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.43 – 8.39 (m, 2H, H_{Ar}) ; 8.30 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 8.05 – 8.01 (m, 2H, H_{Ar})



; 7.80 (br s, 1H, NH) ; 7.31 (br s, 2H, NH₂) ; 6.12 (d, *J* = 2.3 Hz, 1H, H_{1'}) ; 5.44 (dd, *J* = 6.3, 2.4 Hz, 1H, H_{2'}) ; 4.91 (dd, *J* = 6.3, 3.1 Hz, 1H, H_{3'}) ; 4.11 (td, *J* = 6.9, 3.1 Hz, 1H, H_{4'}) ; 2.83 (t, *J* = 7.0 Hz, 2H, CH₂ Et) ; 2.62 (dd, *J* = 13.4, 7.3 Hz, 1H, H_{5'}) ; 2.48 – 2.33 (m, 5H, H_{5''}, H_a, CH₂ Et) ; 1.51 (s, 3H, CH₃ isopr) ; 1.32 (s, 3H, CH₃ isopr) ; 0.78 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆) ; 152.7 (C₂) ; 149.5 (C_q Ar) ; 148.7 (C₄) ; 146.2 (C_q Ar) ; 140.1 (C₈) ; 128.0 (C_{Ar}) ; 124.6 (C_{Ar}) ; 119.2 (C₅) ; 113.1 (C_q isopr) ; 89.1 (C_{1'}) ; 84.5 (C_{4'}) ; 82.9 (C_{2'}) ; 82.8 (C_{3'}) ; 55.0 (C_{5'}) ; 52.6 (CH₂ Et) ; 47.6 (C_a) ; 40.8 (CH₂ Et) ; 26.9 (CH₃ isopr) ; 25.2 (CH₃ isopr) ; 11.3 (C_b). HRMS (ESI+): *m/z* calc. for C₂₃H₃₁N₈O₇S [M+H]⁺: 563.2031, Found 563.2031.


N-(2-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(ethylamino)ethyl)-4-cyanobenzenesulfonamide (51).

Following method A with **48** (110 mg, 0.29 mmol, 1.00 eq) and 4-cyanobenzenesulfonyl chloride (73 mg, 0.36 mmol, 1.25 eq), **51** was obtained as a white solid (60 mg, 38%). R_f 0.49 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.30 (s, 1H, H₈); 8.14 (s, 1H, H₂); 8.09 – 8.06 (m, 2H, H_{Ar}); 7.95 – 7.92 (m, 2H, H_{Ar}); 7.71 (br s, 1H, NH); 7.32 (br s, 2H, NH₂); 6.12 (d, $J = 2.3$ Hz, 1H, H_{1'}); 5.45 (dd, $J = 6.3, 2.4$ Hz, 1H, H_{2'}); 4.92 (dd, $J = 6.3, 3.1$ Hz, 1H, H_{3'}); 4.11 (td, $J = 7.0, 3.1$ Hz, 1H, H_{4'}); 2.80 (t, $J = 7.0$ Hz, 2H, CH_{2 Et}); 2.62 (dd, $J = 13.4, 7.4$ Hz, 1H, H_{5'}); 2.47 – 2.33 (m, 5H, H_{5''}, H_a, CH_{2 Et}); 1.52 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}); 0.78 (t, $J = 7.1$ Hz, 3H, H_b). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 148.7 (C₄); 144.7 (CN); 140.1 (C₈); 133.4 (C_{Ar}); 127.2 (C_{Ar}); 119.2 (C₅); 117.8 (C_{q Ar}); 114.8 (C_{q Ar}); 113.1 (C_{q isopr}); 89.1 (C_{1'}); 84.5 (C_{4'}); 82.9 (C_{2'}); 82.8 (C_{3'}); 54.9 (C_{5'}); 52.6 (CH_{2 Et}); 47.6 (C_a); 40.7 (CH_{2 Et}); 27.0 (CH_{3 isopr}); 25.2 (CH_{3 isopr}); 11.3 (C_b). **HRMS** (ESI+): m/z calc. for C₂₄H₃₁N₈O₅S [M+H]⁺: 543.2133, Found 543.2136.




N-(2-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(ethylamino)ethyl)-4-methylbenzenesulfonamide (52).

Following method A with **48** (130 mg, 0.34 mmol, 1.00 eq) and 4-methylbenzenesulfonyl chloride (82 mg, 0.43 mmol, 1.25 eq), **52** was obtained as a white solid (120 mg, 66%). R_f 0.56 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.30 (s, 1H, H₈); 8.14 (s, 1H, H₂); 7.67 – 7.63 (m, 2H, H_{Ar}); 7.37 (m, 2H, H_{Ar}); 7.32 (br. s, 2H, NH₂); 7.26 (t, $J = 5.8$ Hz, 1H, NH); 6.12 (d, $J = 2.3$ Hz, 1H, H_{1'}); 5.43 (dd, $J = 6.3, 2.4$ Hz, 1H, H_{2'}); 4.91 (dd, $J = 6.3, 3.1$ Hz, 1H, H_{3'}); 4.11 (td, $J = 7.2, 3.1$ Hz, 1H, H_{4'}); 2.74 (dd, $J = 13.4, 7.0$ Hz, 2H, CH_{2 Et}); 2.62 (dd, $J = 13.4, 7.6$ Hz, 1H, H_{5'}); 2.47 – 2.32 (m, 8H, H_{5''}, H_a, CH_{3 Ar}, CH_{2 Et}); 1.52 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}); 0.79 (t, $J = 7.1$ Hz, 3H, H_b). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C_v); 148.7 (C₄); 142.6 (C_{q Ar}); 140.1 (C₈); 137.5 (C_{q Ar}); 129.6 (C_{Ar}); 126.5 (C_{Ar}); 119.2 (C₅); 113.1 (C_{q isopr}); 89.1 (C_{1'}); 84.4 (C_{4'}); 83.0 (C_{2'}); 82.8 (C_{3'}); 55.1 (C_{5'}); 52.5 (CH_{2 Et}); 47.7 (C_a); 40.7 (CH_{2 Et}); 27.0 (CH_{3 isopr}); 25.2 (CH_{3 isopr}); 20.9 (CH_{3 Ar}); 11.4 (C_b). **HRMS** (ESI+): m/z calc. for C₂₄H₃₄N₇O₅S [M+H]⁺: 532.2337, Found 532.2340.



N-(2-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(ethylamino)ethyl)-4-(trifluoromethyl)benzenesulfonamide (53).


Following method A with **48** (117 mg, 0.31 mmol, 1.00 eq) and 4-trifluoromethylbenzenesulfonyl chloride (95 mg, 0.39 mmol, 1.25 eq), **53** was obtained as a white solid (78 mg, 43%). R_f 0.45 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.30 (s, 1H, H₈); 8.14 (s, 1H, H₂); 8.01 – 7.96 (m, 4H, H_{Ar}); 7.67 (br s, 1H, NH); 7.32 (br s, 2H, NH₂); 6.12 (d, $J = 2.3$ Hz, 1H, H_{1'}); 5.44 (dd, $J = 6.3, 2.4$ Hz, 1H, H_{2'}); 4.92 (dd, $J = 6.3, 3.1$ Hz, 1H, H_{3'}); 4.12 (td, $J = 7.0, 3.1$ Hz, 1H, H_{4'}); 2.81 (m, 2H, CH_{2 Et}); 2.63 (dd, $J = 13.4, 7.5$ Hz, 1H, H_{5'}); 2.49 – 2.31 (m, 5H, H_{5''}, H_a, CH_{2 Et}); 1.51 (s, 3H, CH_{3 isopr}); 1.32 (s, 3H, CH_{3 isopr}); 0.77 (t, $J = 7.1$ Hz, 3H, H_b). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 148.7 (C₄); 144.4 (C_{q Ar}); 140.1 (C₈); 132.4, 132.2, 132.0, 131.8 (CF₃); 127.4 (C_{Ar}); 126.4 (C_{Ar}); 126.2, 124.4, 122.6, 120.8 (C_{q Ar}); 119.2 (C₅); 113.1 (C_{q isopr}); 89.1 (C_{1'}); 84.5 (C_{4'}); 82.9 (C_{2'});



; 82.8 (C_{3'}); 55.0 (C_{5'}); 52.6 (CH_{2 Et}); 47.6 (C_a); 40.8 (CH_{2 Et}); 26.9 (CH_{3 isopr}); 25.2 (CH_{3 isopr}); 11.3 (C_b).
HRMS (ESI+): m/z calc. for C₂₄H₃₁F₃N₇O₅S [M+H]⁺: 586.2054, Found 586.2060.

N-(2-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)(ethyl)amino)ethyl)benzenesulfonamide


(14). Following method C with intermediate **49** (117 mg, 0.23 mmol, 1.00 eq), **14** was obtained as a white solid (95 mg, 88%). R_f 0.23 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.30 (s, 1H, H₈); 8.13 (s, 1H, H₂); 7.77–7.74 (m, 2H, H_{Ar}); 7.63–7.59 (m, 1H, H_{Ar}); 7.58–7.54 (m, 2H, H_{Ar}); 7.42 (t, *J* = 5.6 Hz, 1H, NH); 7.28 (br s, 2H, NH₂); 5.83 (d, *J* = 5.2



Hz, 1H, H_{1'}); 5.44 (br s, 1H, OH_{2'}); 5.16 (br s, 1H, OH_{3'}); 4.60 (t, *J* = 5.2 Hz, 1H, H_{2'}); 4.05 (t, *J* = 4.9 Hz, 1H, H_{3'}); 3.88 (dt, *J* = 6.6, 4.8 Hz, 1H, H_{4'}); 2.78 (m, 2H, CH_{2 Et}); 2.73 (dd, *J* = 13.9, 5.0 Hz, 1H, H_{5'}); 2.61–2.56 (dd, *J* = 13.9, 6.9 Hz, 1H, H_{5''}); 2.47–2.38 (m, 4H, CH_{2 Et}, H_a); 0.84 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.6 (C₂); 149.4 (C₄); 140.5 (C_{q Ar}); 139.9 (C₈); 132.3 (C_{Ar}); 129.2 (C_{Ar}); 126.4 (C_{Ar}); 119.2 (C₅); 87.6 (C_{1'}); 82.5 (C_{4'}); 72.6 (C_{2'}); 71.7 (C_{3'}); 55.8 (C_{5'}); 52.8 (CH_{2 Et}); 47.8 (C_a); 40.8 (CH_{2 Et}); 11.6 (C_b). **HRMS** (ESI+): m/z calc. for C₂₀H₂₈N₇O₅S [M+H]⁺: 478.1867, Found 478.1863.

N-(2-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)(ethyl)amino)ethyl)-4-nitrobenzenesulfonamide


(15). Following method C with intermediate **50** (73 mg, 0.13 mmol, 1.00 eq), **15** was obtained as a white solid (65 mg, 96%). R_f 0.32 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.40–8.37 (m, 2H, H_{Ar}); 8.30 (s, 1H, H₈); 8.13 (s, 1H, H₂); 8.03–8.00 (m, 2H, H_{Ar}); 7.85 (s, 1H, NH); 7.27 (s, 2H, NH₂); 5.83 (d, *J* = 5.1 Hz, 1H, H_{1'});



5.45 (br s, 1H, OH_{2'}); 5.16 (br s, 1H, OH_{3'}); 4.59 (t, *J* = 5.2 Hz, 1H, H_{2'}); 4.05 (t, *J* = 4.9 Hz, 1H, H_{3'}); 3.88 (m, 1H, H_{4'}); 2.85 (m, 2H, CH_{2 Et}); 2.74 (dd, *J* = 13.9, 4.9 Hz, 1H, H_{5'}); 2.60 (dd, *J* = 13.9, 6.9 Hz, 1H, H_{5''}); 2.49–2.41 (m, 4H, H_a, CH_{2 Et}); 0.85 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.6 (C₂); 149.5 (C_{q Ar}); 149.3 (C₄); 146.2 (C_{q Ar}); 139.8 (C₈); 128.0 (C_{Ar}); 124.6 (C_{Ar}); 119.2 (C₅); 87.6 (C_{1'}); 82.5 (C_{4'}); 72.6 (C_{2'}); 71.7 (C_{3'}); 55.7 (C_{5'}); 52.9 (CH_{2 Et}); 47.8 (C_a); 40.9 (CH_{2 Et}); 11.6 (C_b). **HRMS** (ESI+): m/z calc. for C₂₀H₂₇N₈O₇S [M+H]⁺: 523.1718, Found 523.1718.

N-(2-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)(ethyl)amino)ethyl)-4-cyanobenzenesulfonamide


(16). Following method C with intermediate **51** (57 mg, 0.11 mmol, 1.00 eq), **16** was obtained as a white solid (42 mg, 80%). R_f 0.24 (1:9 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.30 (s, 1H, H₈); 8.14 (s, 1H, H₂); 8.07–8.04 (m, 2H, H_{Ar}); 7.94–7.90 (m, 2H, H_{Ar}); 7.77 (br s, 1H, NH); 7.28 (s, 2H, NH₂); 5.84 (d, *J* = 5.1 Hz, 1H, H_{1'});



5.45 (br s, 1H, OH_{2'}); 5.17 (br s, 1H, OH_{3'}); 4.60 (t, *J* = 5.2 Hz, 1H, H_{2'}); 4.05 (t, *J* = 4.9 Hz, 1H, H_{3'}); 3.88 (dt, *J* = 6.7, 4.8 Hz, 1H, H_{4'}); 2.83 (br s, 2H, CH_{2 Et}); 2.74 (dd, *J* = 13.9, 4.9 Hz, 1H, H_{5'}); 2.60 (dd, *J* = 13.9, 6.9 Hz, 1H, H_{5''}); 2.49–2.41 (m, 4H, CH_{2 Et}, H_a); 0.84 (t, *J* = 7.1 Hz, 3H, H_b). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.6 (C₂); 149.3 (C₄); 144.8 (C_{CN}); 139.9 (C₈); 133.4 (C_{Ar}); 127.2 (C_{Ar}); 119.2 (C₅); 117.8 (C_{q Ar}); 114.8 (C_{q Ar}); 87.6 (C_{1'}); 82.5 (C_{4'}); 72.6 (C_{2'}); 71.8 (C_{3'}); 55.7 (C_{5'}); 52.9 (CH_{2 Et}); 47.8 (C_a); 40.8 (CH_{2 Et}); 11.6 (C_b). **HRMS** (ESI+): m/z calc. for C₂₁H₂₇N₈O₅S [M+H]⁺: 503.1820, Found 503.1819.


N-(2-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)(ethyl)amino)ethyl)-4-methylbenzenesulfonamide (17).

Following method **C** with intermediate **52** (116 mg, 0.22 mmol, 1.00 eq), **17** was obtained as a white solid (91 mg, 85%). R_f 0.31 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.30 (s, 1H, H₈) ; 8.13 (s, 1H, H₂) ; 7.65 – 7.61 (m, 2H, H_{Ar}) ; 7.34 (m, 2H, H_{Ar}) ; 7.32 (t, J = 5.8 Hz, 1H, NH) ; 7.28 (br. s, 2H, NH₂) ; 5.84 (d, J = 5.2 Hz, 1H, H_{1'}) ; 5.44 (br s, 1H, OH_{2'}) ; 5.16 (br s, 1H, OH_{3'}) ; 4.60 (t, J = 5.2 Hz, 1H, H_{2'}) ; 4.05 (t, J = 4.9 Hz, 1H, H_{3'}) ; 3.88 (dt, J = 6.6, 4.9 Hz, 1H, H_{4'}) ; 2.79 – 2.70 (m, 3H, CH_{2 Et}, H_{5'}) ; 2.59 (dd, J = 13.9, 6.8 Hz, 1H, H_{5''}) ; 2.49 – 2.40 (m, 4H, CH_{2 Et}, H_a) ; 2.36 (s, 3H, CH_{3 Ar}) ; 0.85 (t, J = 7.1 Hz, 3H, H_b). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) 156.1 (C₆) ; 152.6 (C₂) ; 149.4 (C₄) ; 142.5 (C_{q Ar}) ; 139.8 (C₈) ; 137.6 (C_{q Ar}) ; 129.6 (C_{Ar}) ; 126.5 (C_{Ar}) ; 119.2 (C₅) ; 87.6 (C_{1'}) ; 82.5 (C_{4'}) ; 72.6 (C_{2'}) ; 71.7 (C_{3'}) ; 55.8 (C_{5'}) ; 52.8 (CH_{2 Et}) ; 47.8 (C_a) ; 40.7 (CH_{2 Et}) ; 20.9 (CH_{3 Ar}) ; 11.6 (C_b). **HRMS** (ESI+): m/z calc. for C₂₁H₃₀N₇O₅S [M+H]⁺: 492.2024, Found 492.2022.



N-(2-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl)(ethyl)amino)ethyl)-4-(trifluoromethyl)benzenesulfonamide (18).


Following method **C** with intermediate **53** (78 mg, 0.13 mmol, 1.00 eq), **18** was obtained as a white solid (53 mg, 73%). R_f 0.30 (1:9 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.31 (s, 1H, H₈) ; 8.13 (s, 1H, H₂) ; 7.96 (q, J = 8.5 Hz, 4H, H_{Ar}) ; 7.73 (br s, 1H, NH) ; 7.28 (br s, 2H, NH₂) ; 5.84 (d, J = 5.1 Hz, 1H, H_{1'}) ; 5.45 (br s, 1H, OH_{2'}) ; 5.16 (br s, 1H, OH_{3'}) ; 4.60 (t, J = 5.2 Hz, 1H, H_{2'}) ; 4.06 (t, J = 4.9 Hz, 1H, H_{3'}) ; 3.89 (dt, J = 6.7, 4.8 Hz, 1H, H_{4'}) ; 2.83 (br s, 2H, CH_{2 Et}) ; 2.74 (dd, J = 13.9, 4.9 Hz, 1H, H_{5'}) ; 2.61 (dd, J = 13.9, 6.9 Hz, 1H, H_{5''}) ; 2.49 – 2.40 (m, 4H, CH_{2 Et}, H_a) ; 0.83 (t, J = 7.1, 3H, H_b). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.4 (C₄) ; 144.5 (C_{q Ar}) ; 139.8 (C₈) ; 132.4, 132.2, 132.0, 131.8 (CF₃) ; 127.4 (C_{Ar}) ; 126.4 (C_{Ar}) ; 126.2, 124.4, 122.6, 120.8 (C_{q Ar}) ; 119.2 (C₅) ; 87.6 (C_{1'}) ; 82.5 (C_{4'}) ; 72.6 (C_{2'}) ; 71.8 (C_{3'}) ; 55.7 (C_{5'}) ; 52.9 (CH_{2 Et}) ; 47.8 (C_a) ; 40.8 (CH_{2 Et}) ; 11.6 (C_b). **HRMS** (ESI+): m/z calc. for C₂₁H₂₇F₃N₇O₅S [M+H]⁺: 546.1741, Found 546.1740.



N-propargyl-N-ethylsulfonamide reagents (J-M)


4-chloro-N-ethyl-N-(prop-2-yn-1-yl)benzenesulfonamide (J).

Following method **D** with reagent **D** (200 mg, 0.87 mmol, 1.00 eq), **J** was obtained as an orange oil (170 mg, 76%). R_f 0.60 (99:1 DCM/MeOH). $^1\text{H-NMR}$ (400 MHz, CDCl₃) δ 7.83 – 7.74 (m, 2H) ; 7.51 – 7.43 (m, 2H) ; 4.16 (d, J = 2.5 Hz, 2H) ; 3.28 (q, J = 7.2 Hz, 2H) ; 2.03 (t, J = 2.5 Hz, 1H) ; 1.20 (t, J = 7.1 Hz, 3H). $^{13}\text{C-NMR}$ (101 MHz, CDCl₃) δ 139.3 (C_{q Ar}), 137.6 (C_{q Ar}), 129.3 (CH_{Ar}), 129.3 (CH_{Ar}), 76.4 (C_{q alkyne}), 74.0 (CH_{alkyne}), 41.4 (CH₂), 35.8 (CH₂), 13.3 (CH₃). **HRMS** (ESI+): m/z calcd for C₁₁H₁₃ClNO₂S [M+H]⁺: 258.0350, Found 258.0350.



4-trifluoromethyl-N-ethyl-N-(prop-2-yn-1-yl)benzenesulfonamide (K).


Following method **D** with reagent **E** (200 mg, 0.76 mmol, 1.00 eq), **K** was obtained as a brown oil (168 mg, 76%). R_f 0.68 (99:1 DCM/MeOH). $^1\text{H-NMR}$ (400 MHz, CDCl₃) δ 7.99 (d, J = 8.2 Hz, 2H) ; 7.77 (d, J = 8.2 Hz, 2H) ; 4.19 (d, J = 2.5 Hz, 1H) ; 3.31 (q, J = 7.2 Hz, 1H) ; 2.01 (t, J = 2.4 Hz, 1H) ; 1.21 (t, J = 7.2 Hz, 2H). $^{13}\text{C-NMR}$ (101 MHz, CDCl₃)



δ 142.7 ($C_{q\ Ar}$), 135.0, 134.7, 134.3, 134.0 ($C_{q\ Ar}$), 128.3 (CH_{Ar}), 126.2 (CH_{Ar}), 127.5, 124.8, 122.1, 119.3 (CF_3), 76.2 ($C_{q\ alkyne}$), 74.1 (CH_{alkyne}), 41.5 (CH_2), 35.8 (CH_2), 13.3 (CH_3). **HRMS (ESI+)**: m/z calcd for $C_{12}H_{13}F_3NO_2S$ $[M+H]^+$: 292.0614, Found 292.0615.


4-fluoro-*N*-ethyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**L**).

Following method **D** with reagent **F** (200 mg, 0.94 mmol, 1.00 eq), **L** was obtained as an orange oil (181 mg, 80%). R_f 0.60 (99:1 DCM/MeOH). **1H -NMR** (400 MHz, $CDCl_3$) δ 7.92 – 7.80 (m, 2H); 7.22 – 7.11 (m, 2H); 4.15 (d, $J = 2.5$ Hz, 2H); 3.28 (q, $J = 7.2$ Hz, 2H); 2.02 (t, $J = 2.5$ Hz, 1H); 1.19 (t, $J = 7.2$ Hz, 3H). **^{13}C -NMR** (101 MHz, $CDCl_3$) δ 166.6, 164.0 (C-F), 135.1, 135.1 ($C_{q\ Ar}$), 130.5, 130.4 (CH_{Ar}), 116.3, 116.1 (CH_{Ar}), 76.4 ($C_{q\ alkyne}$), 73.9 (CH_{alkyne}), 41.4 (CH_2), 35.7 (CH_2), 13.3 (CH_3). **HRMS (ESI+)**: m/z calcd for $C_{11}H_{13}FNO_2S$ $[M+H]^+$: 242.0646, Found 242.0647.



4-methoxy-*N*-ethyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide (**M**).

Following method **D** with reagent **G** (200 mg, 0.89 mmol, 1.00 eq), **M** was obtained as a yellow oil (151 mg, 67%). R_f 0.50 (99:1 DCM/MeOH). **1H -NMR** (400 MHz, $CDCl_3$) δ 7.83 – 7.73 (m, 2H); 7.02 – 6.91 (m, 2H); 4.13 (d, $J = 2.5$ Hz, 2H); 3.86 (s, 3H); 3.26 (q, $J = 7.2$ Hz, 2H); 2.02 (t, $J = 2.5$ Hz, 1H); 1.18 (t, $J = 7.1$ Hz, 3H). **^{13}C -NMR** (101 MHz, $CDCl_3$) δ 163.1




($C_{q\ Ar}$), 130.7 ($C_{q\ Ar}$), 129.9 (CH_{Ar}), 114.1 (CH_{Ar}), 73.6 ($C_{q\ alkyne}$), 73.6 (CH_{alkyne}), 55.7 (OCH_3), 41.3 (CH_2), 35.8 (CH_2), 13.3 (CH_3). **HRMS (ESI+)**: m/z calcd for $C_{12}H_{16}NO_3S$ $[M+H]^+$: 254.0845, Found 254.0844.

N-arylsulfonamide adenosine analogues with an *N*-methyltriazole linker (**19-31**)


N-[1-[(2*R*,5*R*)-5-(6-amino-9*H*-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-1*H*-1,2,3-triazol-4-yl]methyl]benzenesulfonamide (**19**).

Following method **E** with 5'-azido-adenosine (54 mg, 0.185 mmol, 1.20 eq) and reagent **A** (30 mg, 0.154 mmol, 1.0 eq), **19** was obtained as a white powder (34 mg, 38%). R_f 0.50 (8:92 MeOH/DCM). **1H -NMR** (600 MHz, $DMSO-d_6$) δ 8.28 (s, 1H, H_8); 8.16 (s, 1H, H_2); 8.08 (t, $J = 6.0$ Hz, 1H, NH); 7.76 – 7.71 (m, 2H, $2H_{Ar}$); 7.67 (s, 1H, $H_{Triazole}$); 7.59 (tt, $J = 6.6, 1.2$ Hz, 1H, H_{Ar}); 7.55 – 7.50 (m, 2H, $2H_{Ar}$); 7.31 (br. s, 2H, NH_2); 5.90 (d, $J = 5.4$ Hz, 1H, $H_{1'}$); 5.59 (d, $J = 5.7$ Hz, 1H, $OH_{2'}$); 5.45 (d, $J = 4.8$ Hz, 1H, $OH_{3'}$); 4.75 – 4.60 (m, 3H, $H_{2'}$, $H_{5'5''}$); 4.23 (q, $J = 4.4$ Hz, 1H, $H_{3'}$); 4.19 (dt, $J = 7.6, 4.3$ Hz, 1H, $H_{4'}$); 4.06 – 3.92 (m, 2H, CH_2 -NH). **^{13}C -NMR** (151 MHz, $DMSO-d_6$) δ 156.1 (C_6); 152.7 (C_2); 149.3 (C_4); 143.3 ($C_{q\ Triazole}$); 140.4 ($C_{q\ Ar}$); 139.9 (C_8); 132.3 (CH_{Ar}); 129.1 (CH_{Ar}); 126.5 (CH_{Ar}); 123.8 ($CH_{Triazole}$); 119.2 (C_5); 87.8 ($C_{1'}$); 82.4 ($C_{4'}$); 72.6 ($C_{2'}$); 71.0 ($C_{3'}$); 51.4 ($C_{5'}$); 38.0 (CH_2 -NH). **HRMS (ESI+)**: m/z calcd for $C_{19}H_{22}N_9O_5S$ $[M+H]^+$: 488.1459, Found 488.1460.



N-[1-[(2*R*,5*R*)-5-(6-amino-9*H*-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-1*H*-1,2,3-triazol-4-yl]methyl]-3-methylbenzene-1-sulfonamide (**20**).


Following method **E** with 5'-azido-adenosine (63 mg, 0.215 mmol, 1.0 eq) and reagent **B** (50 mg, 0.239 mmol, 1.1 eq), **20** was obtained as a white powder (39 mg, 36%). R_f 0.50 (8:92 MeOH/DCM). **1H -NMR** (600 MHz, $DMSO-d_6$) δ 8.28 (s, 1H, H_8); 8.16 (s, 1H, H_2); 8.02 (t, $J = 6.0$ Hz, 1H, NH); 7.67 (s, 1H, $H_{Triazole}$); 7.57 – 7.51 (m, 2H, $2H_{Ar}$); 7.44 – 7.36 (m, 2H, $2H_{Ar}$); 7.31 (br. s, 2H, NH_2); 5.59 (d, $J = 5.4$ Hz, 1H, $H_{1'}$); 5.59 (br. s, 1H, $OH_{2'}$); 5.46 (br. s, 1H, $OH_{3'}$); 4.75 – 4.62 (m, 3H, $H_{2'}$, $H_{5'5''}$); 4.27 – 4.21 (m, 1H, $H_{3'}$); 4.19 (dt,



$J = 7.7, 4.3$ Hz, 1H, $H_{4'}$); 4.04 – 3.93 (m, 2H, CH_2 -NH); 2.35 (s, 3H, CH_3). ^{13}C -NMR (151 MHz, DMSO- d_6) δ 156.1 (C_6); 152.7 (C_2); 149.3 (C_4); 143.3 (C_q Triazole); 140.3 (C_8); 139.9 ($C_{q Ar}$); 138.7 ($C_{q Ar}$); 132.9 (CH_{Ar}); 128.9 (CH_{Ar}); 126.7 (CH_{Ar}); 123.8 ($CH_{Triazole}$); 123.6 (CH_{Ar}); 119.2 (C_5); 87.8 ($C_{1'}$); 82.4 ($C_{4'}$); 72.6 ($C_{2'}$); 71.0 ($C_{3'}$); 51.4 ($C_{5'}$); 38.0 (CH_2 -NH); 20.8 (CH_3). HRMS (ESI+): m/z calcd for $C_{20}H_{24}N_9O_5S$ [M+H] $^+$: 502.1616, Found 502.1617.

N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-4-methylbenzene-1-sulfonamide (21).


Following method E with 5'-azido-adenosine (77 mg, 0.263 mmol, 1.10 eq) and reagent C (50 mg, 0.239 mmol, 1.0 eq), **21** was obtained as a white powder (73 mg, 61%). R_f 0.50 (1:9 MeOH/DCM). 1H -NMR (600 MHz, DMSO- d_6) δ 8.28 (s, 1H, H_8); 8.15 (s, 1H, H_2); 7.98 (t, $J = 6.0$ Hz, 1H, NH); 7.69 (s, 1H, $H_{Triazole}$);



7.64 – 7.60 (m, 2H, $2H_{Ar}$); 7.36 – 7.27 (m, 4H, $2H_{Ar}$, NH_2); 5.90 (d, $J = 5.4$ Hz, 1H, $H_{1'}$); 5.59 (d, $J = 5.6$ Hz, 1H, $OH_{2'}$); 5.46 (d, $J = 4.7$ Hz, 1H, $OH_{3'}$); 4.75 – 4.62 (m, 3H, $H_{2'}$, $H_{5'5''}$); 4.25 – 4.16 (m, 2H, $H_{3'}$, $H_{4'}$); 4.01 – 3.87 (m, 2H, CH_2 -NH); 2.36 (s, 3H, CH_3). ^{13}C -NMR (151 MHz, DMSO- d_6) δ 156.1 (C_6); 152.7 (C_2); 149.3 (C_4); 143.3 (C_q Triazole); 142.6 ($C_{q Ar}$); 139.9 (C_8); 137.4 ($C_{q Ar}$); 129.5 (CH_{Ar}); 126.6 (CH_{Ar}); 123.8 ($CH_{Triazole}$); 119.2 (C_5); 87.8 ($C_{1'}$); 82.4 ($C_{4'}$); 72.6 ($C_{2'}$); 71.0 ($C_{3'}$); 51.4 ($C_{5'}$); 38.0 (CH_2 -NH); 20.9 (CH_3). HRMS (ESI+): m/z calcd for $C_{20}H_{24}N_9O_5S$ [M+H] $^+$: 502.1616, Found 502.1619.

N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-4-chlorobenzene-1-sulfonamide (22).


Following method E with 5'-azido-adenosine (57 mg, 0.195 mmol, 1.0 eq) and reagent D (50 mg, 0.218 mmol, 1.1 eq), **22** was obtained as a white powder (43 mg, 38%). R_f 0.50 (8:92 MeOH/DCM). 1H -NMR (600 MHz, DMSO- d_6) δ 8.28 (s, 1H, H_8); 8.19 (t, $J = 6.0$ Hz, 1H, NH); 8.16 (s, 1H, H_2); 7.75 – 7.70 (m, 3H, $2H_{Ar}$,



$H_{Triazole}$); 7.63 – 7.56 (m, 2H, $2H_{Ar}$); 7.31 (br. s, 2H, NH_2); 5.91 (d, $J = 5.4$ Hz, 1H, $H_{1'}$); 5.59 (d, $J = 5.8$ Hz, 1H, $OH_{2'}$); 5.45 (d, $J = 5.1$ Hz, 1H, $OH_{3'}$); 4.75 – 4.62 (m, 3H, $H_{2'}$, $H_{5'5''}$); 4.27 – 4.16 (m, 2H, $H_{3'}$, $H_{4'}$); 4.06 – 3.94 (m, 2H, CH_2 -NH). ^{13}C -NMR (151 MHz, DMSO- d_6) δ 156.1 (C_6); 152.7 (C_2); 149.3 (C_4); 143.1 (C_q Triazole); 139.9 (C_8); 139.3 ($C_{q Ar}$); 137.2 ($C_{q Ar}$); 129.2 (CH_{Ar}); 128.5 (CH_{Ar}); 123.9 ($CH_{Triazole}$); 119.3 (C_5); 87.8 ($C_{1'}$); 82.4 ($C_{4'}$); 72.6 ($C_{2'}$); 71.0 ($C_{3'}$); 51.4 ($C_{5'}$); 37.9 (CH_2 -NH). HRMS (ESI+): m/z calcd for $C_{19}H_{21}ClN_9O_5S$ [M+H] $^+$: 522.1069, Found 522.1063.

N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-4-trifluoromethyl benzene-1-sulfonamide (23).

Following method E with 5'-azido-adenosine (50 mg, 0.171 mmol, 1.0 eq) and reagent E (50 mg, 0.189 mmol, 1.10 eq), **23** was obtained as a white powder (24 mg, 23%). R_f 0.57 (8:92 MeOH/DCM). 1H -NMR (600 MHz, DMSO- d_6) δ 8.37 (t, $J = 6.0$ Hz, 1H, NH); 8.27 (s, 1H, H_8); 8.15 (s, 1H, H_2); 7.96




– 7.90 (m, 4H, $4H_{Ar}$); 7.75 (s, 1H, $H_{Triazole}$); 7.31 (br. s, 2H, NH_2); 5.90 (d, $J = 5.4$ Hz, 1H, $H_{1'}$); 5.59 (d, $J = 5.9$ Hz, 1H, $OH_{2'}$); 5.45 (d, $J = 5.1$ Hz, 1H, $OH_{3'}$); 4.73 – 4.62 (m, 3H, $H_{2'}$, $H_{5'5''}$); 4.27 – 4.14 (m, 2H, $H_{3'}$, $H_{4'}$); 4.10 – 3.97 (m, 2H, CH_2 -NH). ^{13}C -NMR (151 MHz, DMSO- d_6) δ 156.1 (C_6); 152.7 (C_2); 149.3 (C_4); 144.4 ($C_{q Ar}$); 142.9 (C_q Triazole); 139.9 (C_8); 132.4, 132.2, 132.0, 131.7 (C -CF $_3$); 128.0, 126.2, 124.4, 122.6 (CF $_3$); 127.5 (CH_{Ar}); 126.3, 126.3 (CH_{Ar}); 124.0 ($CH_{Triazole}$); 119.3 (C_5); 87.8 ($C_{1'}$); 82.4 ($C_{4'}$); 72.5 ($C_{2'}$);

71.0 (C_{3'}); 51.3 (C_{5'}); 37.9 (CH₂-NH). **HRMS** (ESI⁺): m/z calcd for C₂₀H₂₁F₃N₉O₅S [M+H]⁺: 556.1333, Found 556.1332.


N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-4-fluorobenzene-1-sulfonamide (24).

Following method E with 5'-azido-adenosine (50 mg, 0.171 mmol, 1.0 eq) and reagent F (50 mg, 0.234 mmol, 1.37 eq), **24** was obtained as a white powder (15 mg, 13%). R_f 0.50 (8:92 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.28 (s, 1H, H₈); 8.19 (t, J = 6.0 Hz, 1H, NH); 8.16 (s, 1H, H₂); 7.75 – 7.70 (m, 3H, 2H_{Ar}, H_{Triazole}); 7.63 – 7.56 (m, 2H, 2H_{Ar}); 7.31 (br. s, 2H, NH₂); 5.91 (d, J = 5.4 Hz, 1H, H_{1'}); 5.59 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.45 (d, J = 5.1 Hz, 1H, OH_{3'}); 4.75 – 4.62 (m, 3H, H_{2'}, H_{5'5''}); 4.27 – 4.16 (m, 2H, H_{3'}, H_{4'}); 4.06 – 3.94 (m, 2H, CH₂-NH). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.7 (C₂); 149.3 (C₄); 143.1 (C_{q Triazole}); 139.9 (C₈); 139.3 (C_{q Ar}); 137.2 (C_{q Ar}); 129.2 (CH_{Ar}); 128.5 (CH_{Ar}); 123.9 (CH_{Triazole}); 119.3 (C₅); 87.8 (C_{1'}); 82.4 (C_{4'}); 72.6 (C_{2'}); 71.0 (C_{3'}); 51.4 (C_{5'}); 37.9 (CH₂-NH). **HRMS** (ESI⁺): m/z calcd for C₁₉H₂₁FN₉O₅S [M+H]⁺: 522.1069, Found 522.1063.




N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-4-methoxybenzene-1-sulfonamide (25).

Following method E with 5'-azido-adenosine (47 mg, 0.161 mmol, 1.0 eq) and reagent G (50 mg, 0.222 mmol, 1.38 eq), **25** was obtained as a white powder (32 mg, 28%). R_f 0.52 (8:92 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.28 (s, 1H, H₈); 8.19 (t, J = 6.0 Hz, 1H, NH); 8.16 (s, 1H, H₂); 7.75 – 7.70 (m, 3H, 2H_{Ar}, H_{Triazole}); 7.63 – 7.56 (m, 2H, 2H_{Ar}); 7.31 (br. s, 2H, NH₂); 5.91 (d, J = 5.4 Hz, 1H, H_{1'}); 5.59 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.45 (d, J = 5.1 Hz, 1H, OH_{3'}); 4.75 – 4.62 (m, 3H, H_{2'}, H_{5'5''}); 4.27 – 4.16 (m, 2H, H_{3'}, H_{4'}); 4.06 – 3.94 (m, 2H, CH₂-NH). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.7 (C₂); 149.3 (C₄); 143.1 (C_{q Triazole}); 139.9 (C₈); 139.3 (C_{q Ar}); 137.2 (C_{q Ar}); 129.2 (CH_{Ar}); 128.5 (CH_{Ar}); 123.9 (CH_{Triazole}); 119.3 (C₅); 87.8 (C_{1'}); 82.4 (C_{4'}); 72.6 (C_{2'}); 71.0 (C_{3'}); 56.5 (OCH₃); 51.4 (C_{5'}); 37.9 (CH₂-NH). **HRMS** (ESI⁺): m/z calcd for C₁₉H₂₁ClN₉O₅S [M+H]⁺: 522.1069, Found 522.1063.



N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-N-ethylbenzene-sulfonamide (26).

Following method E with 5'-azido-adenosine (61 mg, 0.209 mmol, 1.1 eq) and reagent H (42 mg, 0.190 mmol, 1.0 eq), **26** was obtained as a white powder (53 mg, 54%). R_f 0.50 (15:85 MeOH/DCM). ¹H-NMR (600 MHz, DMSO-*d*₆) δ 8.27 (s, 1H, H₈); 8.15 (s, 1H, H₂); 7.77 – 7.70 (m, 3H, H_{Triazole}, 2H_{Ar}); 7.60 (tt, J = 6.6, 1.2 Hz, 1H, H_{Ar}); 7.55 – 7.49 (m, 2H, 2H_{Ar}); 7.55 – 7.50 (m, 2H, 2H_{Ar}); 7.31 (br. s, 2H, NH₂); 5.91 (d, J = 5.3 Hz, 1H, H_{1'}); 5.60 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.45 (d, J = 4.9 Hz, 1H, OH_{3'}); 4.76 – 4.63 (m, 3H, H_{2'}, H_{5'5''}); 4.41 – 4.30 (m, 2H, H_{3'}, H_{4'}); 4.28 – 4.16 (m, 2H, CH₂-NH); 3.10 (q, J = 7.1 Hz, 2H, CH₂-CH₃); 0.91 (t, J = 7.1 Hz, 3H, CH₂-CH₃). ¹³C-NMR (151 MHz, DMSO-*d*₆) δ 156.1 (C₆); 152.7 (C₂); 149.2 (C₄); 142.4 (C_{q Triazole}); 139.9 (C₈); 139.4 (C_{q Ar}); 132.6 (CH_{Ar}); 129.2 (CH_{Ar}); 126.8 (CH_{Ar}); 124.6 (CH_{Triazole}); 119.2 (C₅); 87.8 (C_{1'}); 82.4 (C_{4'}); 72.6 (C_{2'}); 71.0 (C_{3'}); 51.3 (C_{5'}); 42.1 (CH₂-CH₃); 41.5 (CH₂-NEt); 13.3 (CH₂-CH₃). **HRMS** (ESI⁺): m/z calcd for C₂₁H₂₆N₉O₅S [M+H]⁺: 516.1772, Found 516.1762.




N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-N-ethyl-4-

methylbenzene-1-sulfonamide (27).

Following method E with 5'-azido-adenosine (55 mg, 0.188 mmol, 0.90 eq) and reagent I (50 mg, 0.211 mmol, 1.0 eq), **27** was obtained as a white powder (34 mg, 30%). R_f 0.50 (8:92 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.27 (s, 1H, H₈); 8.15 (s, 1H, H₂); 7.76 (s, 1H, H_{Triazole}); 7.64 – 7.58 (m, 2H, 2H_{Ar}); 7.39 – 7.24 (m, 4H, 2H_{Ar}, NH₂); 5.91 (d, J = 5.3 Hz, 1H, H_{1'}); 5.60 (d, J = 5.8 Hz, 1H, OH_{2'}); 5.45 (d, J = 4.8 Hz, 1H, OH_{3'}); 4.77 – 4.63 (m, 3H, H_{2'}, H_{5'5''}); 4.39 – 4.26 (m, 2H, CH₂-NH); 4.26 – 4.17 (m, 2H, H_{3'}, H_{4'}); 3.07 (q, J = 7.1 Hz, 2H, CH₂-CH₃); 2.36 (s, 3H, CH₃); 0.90 (t, J = 7.1 Hz, 3H, CH₂-CH₃).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 149.2 (C₄); 143.0 (C_{q Triazole}); 142.5 (C_{q Ar}); 139.9 (C₈); 136.5 (C_{q Ar}); 129.7 (CH_{Ar}); 126.8 (CH_{Ar}); 124.6 (CH_{Triazole}); 119.2 (C₅); 87.8 (C_{1'}); 82.3 (C_{4'}); 72.6 (C_{2'}); 70.9 (C_{3'}); 51.3 (C_{5'}); 42.1 (CH₂-CH₃); 41.5 (CH₂-NEt); 20.9 (CH₃); 13.3 (CH₂-CH₃). **HRMS** (ESI+): m/z calcd for C₂₂H₂₈N₉O₅S [M+H]⁺: 530.1929, Found 530.1930.




N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-N-ethyl-4-

chlorobenzene-1-sulfonamide (28).

Following method E with 5'-azido-adenosine (49 mg, 0.168 mmol, 1.0 eq) and reagent J (60 mg, 0.233 mmol, 1.38 eq), **28** was obtained as a white powder (43 mg, 34%). R_f 0.50 (15:85 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.26 (s, 1H, H₈); 8.14 (s, 1H, H₂); 7.83 (s, 1H, H_{Triazole}); 7.78 – 7.71 (m, 2H, 2H_{Ar}); 7.63 – 7.54 (m, 2H, 2H_{Ar}); 7.32 (br.s, 2H, NH₂); 5.91 (d, J = 5.3 Hz, 1H, H_{1'}); 5.60 (d, J = 5.7 Hz, 1H, OH_{2'}); 5.46 (d, J = 4.2 Hz, 1H, OH_{3'}); 4.76 – 4.66 (m, 3H, H_{2'}, H_{5'5''}); 4.39 – 4.31 (m, 2H, CH₂-NH); 4.28 – 4.18 (m, 2H, H_{3'}, H_{4'}); 3.11 (q, J = 7.1 Hz, 2H, CH₂-CH₃); 0.92 (t, J = 7.1 Hz, 3H, CH₂-CH₃).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.7 (C₂); 149.2 (C₄); 142.3 (C_{q Triazole}); 139.9 (C₈); 138.3 (C_{q Ar}); 137.6 (C_{q Ar}); 129.3 (CH_{Ar}); 128.8 (CH_{Ar}); 124.7 (CH_{Triazole}); 119.2 (C₅); 87.9 (C_{1'}); 82.2 (C_{4'}); 72.6 (C_{2'}); 70.9 (C_{3'}); 51.3 (C_{5'}); 42.2 (CH₂-CH₃); 41.5 (CH₂-NEt); 13.4 (CH₂-CH₃). **HRMS** (ESI+): m/z calcd for C₂₁H₂₅ClN₉O₅S [M+H]⁺: 549.9905, Found 549.9915.




N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-N-ethyl-4-


trifluoromethylbenzene-1-sulfonamide (29).

Following method E with 5'-azido-adenosine (43 mg, 0.147 mmol, 1.0 eq) and reagent K (60 mg, 0.206 mmol, 1.40 eq), **29** was obtained as a white powder (32 mg, 27%). R_f 0.64 (15:85 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.27 (s, 1H, H₈); 8.15 (s, 1H, H₂); 8.01 – 7.87 (m, 4H, 4H_{Ar}); 7.85 (s, 1H, H_{Triazole}); 7.32 (br.s, 2H, NH₂); 5.90 (d, J = 5.3 Hz, 1H, H_{1'}); 5.61 (d, J = 5.7 Hz, 1H, OH_{2'}); 5.46 (d, J = 4.6 Hz, 1H, OH_{3'}); 4.75 – 4.63 (m, 3H, H_{2'}, H_{5'5''}); 4.45 – 4.34 (m, 2H, CH₂-NH); 4.26 – 4.18 (m, 2H, H_{3'}, H_{4'}); 3.15 (q, J = 7.1 Hz, 2H, CH₂-CH₃); 0.93 (t, J = 7.1 Hz, 3H, CH₂-CH₃).


$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆); 152.6 (C₂); 149.3 (C₄); 143.3 (C_{q Ar}); 142.1 (C_{q Triazole}); 140.0 (C₈); 132.6, 132.4, 132.2, 132.0 (C-CF₃); 127.8 (CH_{Ar}); 126.4, 126.4 (CH_{Ar}); 126.2, 124.3, 122.5, 120.7 (CF₃); 124.8 (CH_{Triazole}); 119.3 (C₅); 87.9 (C_{1'}); 82.2 (C_{4'}); 72.5 (C_{2'}); 70.9 (C_{3'}); 51.2 (C_{5'}); 42.4 (CH₂-CH₃); 41.6 (CH₂-NEt); 13.4 (CH₂-CH₃). **HRMS** (ESI+): m/z calcd for C₂₂H₂₅F₃N₉O₅S [M+H]⁺: 583.5541, Found 583.5539.



N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-N-ethyl-4-fluorobenzene-1-sulfonamide (30). Following method E with 5'-azido-adenosine (52 mg, 0.177 mmol, 1.0 eq) and reagent L (60 mg, 0.249 mmol, 1.40 eq), **30** was obtained as a white powder (36 mg, 38%). R_f 0.48 (15:85 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.27 (s, 1H, H₈) ; 8.15 (s, 1H, H₂) ; 7.83 – 7.77 (m, 3H, H_{Triazole}, 2H_{Ar}) ; 7.40 – 7.26 (m, 4H, 2H_{Ar}, NH₂) ; 5.90 (d, J = 5.3 Hz, 1H, H_{1'}) ; 5.61 (d, J = 5.8 Hz, 1H, OH_{2'}) ; 5.46 (d, J = 4.4 Hz, 1H, OH_{3'}) ; 4.74 – 4.64 (m, 3H, H_{2'}, H_{5'5''}) ; 4.39 – 4.30 (m, 2H, CH₂-NH) ; 4.28 – 4.17 (m, 2H, H_{3'}, H_{4'}) ; 3.11 (q, J = 7.1 Hz, 2H, CH₂-CH₃) ; 0.92 (t, J = 7.1 Hz, 3H, CH₂-CH₃). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 156.1 (C₆) ; 152.6 (C₂) ; 149.3 (C₄) ; 142.3 (C_{q Triazole}) ; 139.9 (C₈) ; 135.8 (C_{q Ar}) ; 129.9, 129.8 (CH_{Ar}) ; 124.7 (CH_{Triazole}) ; 119.3 (C₅) ; 116.4, 116.3 (CH_{Ar}) ; 87.8 (C_{1'}) ; 82.2 (C_{4'}) ; 72.6 (C_{2'}) ; 70.9 (C_{3'}) ; 51.3 (C_{5'}) ; 42.1 (CH₂-CH₃) ; 41.6 (CH₂-NEt) ; 13.3 (CH₂-CH₃). **HRMS** (ESI+): m/z calcd for C₂₁H₂₅FN₉O₅S [M+H]⁺: 533.5400, Found 533.5397.



N-[(1-[(2R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl)-1H-1,2,3-triazol-4-yl]methyl]-N-ethyl-4-methoxybenzene-1-sulfonamide (31). Following method E with 5'-azido-adenosine (50 mg, 0.171 mmol, 1.0 eq) and reagent M (60 mg, 0.240 mmol, 1.40 eq), **31** was obtained as a white powder (21 mg, 23%). R_f 0.42 (15:95 MeOH/DCM). $^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ 8.26 (s, 1H, H₈) ; 8.14 (s, 1H, H₂) ; 7.79 (s, 1H, H_{Triazole}) ; 7.70 – 7.64 (m, 2H, , 2H_{Ar}) ; 7.32 (br.s, 2H, NH₂) ; 7.07 – 7.01 (m, 2H, 2H_{Ar}) ; 5.90 (d, J = 5.3 Hz, 1H, H_{1'}) ; 5.61 (d, J = 5.8 Hz, 1H, OH_{2'}) ; 5.46 (d, J = 4.4 Hz, 1H, OH_{3'}) ; 4.76 – 4.65 (m, 3H, H_{2'}, H_{5'5''}) ; 4.36 – 4.25 (m, 2H, CH₂-NH) ; 4.25 – 4.18 (m, 2H, H_{3'}, H_{4'}) ; 3.82 (s, 3H, OMe) ; 3.06 (q, J = 7.1 Hz, 2H, CH₂-CH₃) ; 0.89 (t, J = 7.1 Hz, 3H, CH₂-CH₃). $^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ 162.3 (C_{q Ar}) ; 156.1 (C₆) ; 152.7 (C₂) ; 149.2 (C₄) ; 142.6 (C_{q Triazole}) ; 139.9 (C₈) ; 129.0 (CH_{Ar}) ; 124.6 (CH_{Triazole}) ; 119.3 (C₅) ; 114.3 (CH_{Ar}) ; 87.8 (C_{1'}) ; 82.3 (C_{4'}) ; 72.6 (C_{2'}) ; 70.9 (C_{3'}) ; 55.6 (OCH₃) ; 51.2 (C_{5'}) ; 42.0 (CH₂-CH₃) ; 41.6 (CH₂-NEt) ; 13.3 (CH₂-CH₃). **HRMS** (ESI+): m/z calcd for C₂₂H₂₈N₉O₆S [M+H]⁺: 545.5836, Found 545.5841.



HPLC analysis of final compounds 1-31

HPLC analysis conditions:

Column: HPLC Column Nucleodur 75/4.6 100-3 C₁₈ EC (Macherey Nagel)



Temperature: 30 °C




Mobile phase: eluent A: 1% ACN in 12.5 mM TEAAc buffer, pH 7; eluent B: 80% ACN in 12.5 mM TEAAc buffer, pH 7




Gradient: 10% to 100% of eluent B during 20 min. Flow rate: 1.0 mL/min

UV detection at wavelength 260 nm




N-arylsulfonamide adenosine analogues with an *N*-ethylthioether (1-8)













***N*-arylsulfonamide adenosine analogues with an *N*-ethylsulfone linker (9-13)**








***N*-arylsulfonamide adenosine analogues with an *N*-ethylamino linker (14-18)**


















N-arylsulfonamide adenosine analogues with an N-methyltriazole linker 19-31





















¹H-NMR and ¹³C-NMR spectra of compounds 1-53



N-arylsulfonamide adenosine analogues with an *N*-ethylthioether linker (33-40 and 1-8)















































































N-arylsulfonamide adenosine analogues with an N-ethylsulfone linker (41-45 and 9-13)



















































N-arylsulfonamide adenosine analogues with an N-ethylamino linker (46-53 and 14-18)


































































N-arylsulfonamide adenosine analogues with an N-methyltriazole linker (19-31)






























































N-ethyl-N-propargyl reagents J-M












IC₅₀ curves of compounds 1-13 against SARS-CoV-2 N7-MTase monitored by FBA

Increasing concentrations of compounds 1-13 (dissolved in 50% DMSO) were incubated with 10 nM SARS-CoV-2 nsp14 in reaction mixture [40 mM Tris-HCl (pH 8.0), 1 mM DTT, 1 mM MgCl₂, 2 μM SAM and 0.1 μM ³H-SAM (Perkin Elmer)] in the presence of 0.7 μM synthetic RNA GpppAC₄. Reactions were incubated at 30°C during 30 min. Values were normalized and fitted with Prism (GraphPad software) using the following equation: $Y=100/(1+((X/IC_{50})^{Hillslope}))$ (n=3; mean value ± SD).

N-arylsulfonamide adenosine analogues with an N-ethylthioether linker (1-8)





***N*-arylsulfonamide adenosine analogues with an *N*-ethylsulfone linker (9-13)**

